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ABSTRACT
Interleukin-7 (IL-7) is an essential cytokine for lymphocyte growth that has the potential
for promoting proliferation and survival. While the survival and proliferative functions of IL-7
are well established, the identities of IL-7 signaling components in pathways other than
JAK/STAT, that accomplish these tasks remain poorly defined. To this end, we used IL-7
dependent T-cells to examine those components necessary for cell growth and survival. Our
studies revealed two novel signal transducers of the IL-7 growth signal: BimL and JunD.
IL-7 promoted the activity of JNK (Jun N-terminal Kinase), and that JNK, in turn, drove
the expression of JunD, a component of the Activating Protein 1 (AP-1) transcription factors.
Inhibition of JNK/JunD blocked glucose uptake and HXKII gene expression, indicating that this
pathway was responsible for promoting HXKII expression. After a bioinformatics survey to
reveal possible JunD-regulated genes activated early in the IL-7 signaling cascade, our search
revealed that JunD could control the expression of proteins involved in signal transduction, cell
survival and metabolism, including Pim-1. Pim-1, an IL-7 induced protein, was inhibited upon
JNK or JunD inhibition.

Our hypothesis that JunD positively regulated proliferation was

confirmed when the proliferation of primary CD8+ T-cells cultured with IL-7 was impaired upon
treatment with JunD siRNA. These results show that the IL-7 signal is more complex than the
JAK/STAT pathway, activating JNK and JunD to induce rapid growth through the expression of
metabolic factors like HXKII and Pim-1.
When metabolic activities are inhibited, cells undergo autophagy, or cell scavenging, to
provide essential nutrients. Pro-apoptotic Bim was evaluated for its involvement in autophagy.
Bim is a BH3-only member of the Bcl-2 family that contributes to T-cell death. Partial rescue of
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T-cells occurs when Bim and the interleukin-7 receptor are deleted, implicating Bim in IL-7deprived T-cell apoptosis. Alternative splicing results in three different isoforms: BimEL, BimL,
and BimS. To study the effect of Bim deficiency and define the function of the major isoforms,
Bim-containing and Bim-deficient T-cells, dependent on IL-7 for growth, were used. Loss of
Bim in IL-7-deprived T-cells delayed apoptosis, but blocked the degradative phase of autophagy.
The conversion of LC3-I to LC3-II was observed in Bim-deficient T-cells, but p62, which is
degraded in autolysosomes, accumulated.

To explain this, BimL, was found to support

acidification of lysosomes associated with autophagic vesicles.

Key findings showed that

inhibition of lysosomal acidification accelerated death upon IL-7 withdrawal only in Bimcontaining T-cells, indicating that in these cells autophagy was protective. IL-7 dependent Tcells lacking Bim were insensitive to inhibition of autophagy or lysosomal acidification. BimL
co-immunoprecipitated with dynein and Lamp1-containing vesicles, indicating BimL could be
an adaptor for dynein to facilitate loading of lysosomes. In Bim deficient T-cells, lysosometracking probes revealed vesicles of less acidic pH. Over-expression of BimL restored acidic
vesicles in Bim deficient T-cells, while other isoforms, BimEL and BimS, associated with
intrinsic cell death. These results reveal a novel role for BimL in lysosomal positioning that may
be required for the formation of functional autolysosomes during autophagy.
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CHAPTER 1: INTRODUCTION
Cytokines are necessary messenger molecules for the immune system, involved in
functions ranging from promoting lymphocyte expansion, and differentiation, to the maintenance
of homeostasis. In general, cytokines are low molecular weight proteins, having a four-alpha
helical bundle structure, that regulate the growth, proliferation, and differentiation of cells
composing the immune system. Typically, cytokines function by binding to specific receptors
on the membranes of targeted cells, regulating the diverse activities that mediate immunity.
Cytokine receptors are composed of two or more polypeptide chains. Typically, one chain is
specific to the individual cytokine receptor and the other chain(s) is shared with multiple
cytokines within the same family. For example, the common γ chain (γc), expressed by most
hematopoetic cells, is essential to establishment of the immune system, and recognizes cytokines
including, but not limited to, interleukins (IL-) 2, 4, 7, 9, and 15.
Alterations to the cytokine signaling cascade can most easily be seen in mice lacking γccontaining receptors. For example, IL-2 is necessary for Treg development [1] and IL-7 is
involved in T cell development and memory T cell homeostasis [2]. IL-4 is essential for the
development and function of T helper 2 cells [3] and IL-15 is required for T cell activation [3].
However, when the receptor for IL-2, IL-4, or IL-15 is deleted, minor phenotypical defects
occur, whereas deletion of IL-7, or a deficiency in its receptor, results in reduced thymic and
peripheral T cell development and lymphopenia, making IL-7 a non-redundant cytokine [4-8].
Deficiencies in the γc receptor chain result in decreased NK and T cell numbers similar to Severe
Combined Immunodeficiency in humans [9, 10].
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The IL-7 receptor is composed of two chains, the common cytokine-receptor γ chain, and
the IL-7Rα, which is expressed exclusively on cells of lymphoid origin [11]. Regulation of IL7α receptor expression occurs through a negative feedback loop, in which the transcription of IL7 suppresses IL7Rα [3]. Mice lacking IL-7 or the IL-7 receptor display reduced lymphoid
progenitor development [12, 13], and impaired expansion and maintenance of naïve T cells [14,
15]. Conversely, excess IL-7 results in the development of lymphoma or leukemia [16]. Taken
together, these studies illustrate the importance of IL-7 in T cell development.
IL-7 itself, is an essential, non-redundant cytokine that is made by stromal and nonlymphoid cells [17], and is produced at such low doses (in the pictogram per milliliter range)
[18] in circulation, that T-cells encounter this signal infrequently. However, the synthesis of IL7 is increased in response to infection [19] or during sepsis [20], or upon T cell depletion [21].
After binding IL-7, the IL-7 receptor heterodimerizes, bringing together the Janus kinases, Jak1
and Jak3, by association between the IL-7Rα and γc, respectively (Fig. 1). Jak1 and Jak3
phosphorylate each other, increasing their kinase activities, and in turn, phosphorylate Y449 on
IL-7Rα to create a docking site for Stat5a/b [22]. Stat5a/b are phosphorylated by JAKs, and
undergo further activation upon forming a homodimer. The Stat5 homodimer translocates to the
nucleus to initiate transcription of various pro-survival genes, such as SOCS1 and Bcl-XL [23].
Previous studies describe Stat5 as the main transducer of the IL-7 signaling pathway, and so less
knowledge exists concerning other pathways induced by IL-7.
IL-7-mediated signaling initiates pathways at multiple stages in the life of a T cell. For
example, IL-7 contributes to the diversity of the thymocyte TCR (T Cell Receptor) repertoire
through de-methylation and histone acetylation of target DNA [24, 25].
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This activity permits

V(D)J recombinase, an enzyme that facilitates transposition events, access to V(D)J genes,
inducing δγ TCR rearrangement [25, 26]. IL-7-mediated signaling is also necessary for mature T
cell survival.

IL-7 sustains this T cell pool by up-regulating pro-survival genes and their

respective proteins, and in addition to those mentioned previously, up-regulates Bcl-2, primarily
through activation of PI3-kinase and AKT and limits expression of pro-apoptotic Bcl-2 family
proteins, Bax and Bad [27]. Questions remain as to whether these are the only targets that IL-7
regulates transcriptionally and post-translationally. In fact, evaluation of immediate response
genes using a cDNA array of IL-7 dependent T cells after a two hour pulse with IL-7, reveals the
potential for many other IL-7-mediated signaling targets, especially those involved in growth
[28].
One homeostatic function of IL-7 is to promote lymphocyte development.
essential for the survival, proliferation and differentiation of immature thymocytes.

IL-7 is
In the

thymus, thymocytes undergo progressive phases of maturation to establish tolerance of self and
eliminate tolerance of foreign antigens. IL-7R is expressed on the surface of double-negative
(DN) (CD4-CD8-) thymocytes, and IL-7 signaling promotes survival of DN thymocytes to
develop a diverse TCR repetoire, by maintaining a balance between Bcl-2 family members and
promoting the recombination of the T cell receptor γ‐chain (TCRγ) [29-31]. To transition to a
double-positive (DP) phase, T cell selection must occur. Essentially, the avidity of the TCR
interaction with the self-peptide:major histocompatibility complex on antigen presenting cells
determines whether a cell will survive [32]. Without the presence of the IL-7R on doublepositive (CD4+CD8+) thymocytes, cells unable to recognize self-peptide:MHC undergo death by
neglect through downregulation of Bcl-2, and reduced inhibition of pro-apoptotic Bim [33, 34].
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IL-7R is once again expressed on single-positive (CD4+ or CD8+) thymocytes and permits
maintenance of the population [35].
IL-7 is also involved in the maintenance of memory T cells.

Following antigen-

activation of naïve T cells, cells undergo clonal expansion, otherwise known as proliferation of
target T cell subsets.

Once invading antigens are destroyed, the immune cell population

undergoes contraction, eliminating excess lymphocytes through apoptosis [36]. What remains is
a subset of antigen-specific T-cells that retain IL-7R expression and develop into memory T cells
and enter a resting phase [7, 37].

IL-7 supports this basal population through promoting

metabolic rate [38] in addition to balancing Bcl-2 and Bim expression [39]. In fact, the level of
IL-7R expression also assists in the differentiation of memory cells. IL-7Rhi effector cells have
potential for further development as memory cell precursors, whereas IL-7Rlo cells are senescent
effector cells [7].
IL-7 signaling and Bim
Homeostasis is in part, maintained through induction of apoptosis. One activity of IL-7 is
to promote pro-survival factors. IL-7 signaling up-regulates the expression of the anti-apoptotic
protein, Bcl-2 [40, 41]. The Bcl-2 family includes anti-apoptotic proteins, such as Bcl-2 and
Bcl-xL, pro-apoptotic members, such as the multi-domain proteins, Bax and Bak, and BH3-only
proteins, Bad, Bid, Bim or Bmf [42] (Fig. 2). Due to the important roles of the Bcl-2 family in T
cell survival, IL-7R-/- immunodeficiency can be partially rescued by overexpression of Bcl-2
[43], and depletion of Bim [44], or Bax [45]. Mice lacking Bim are unable to delete autoreactive
T cells, but coupled with the absence of IL-7R, Bim deficiency can restore partial T cell volumes
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[33, 34, 44]. Being that the addition of IL-7 or Bim (or Bax) deficiency, does not completely
rescue cells from death, indicates involvement of additional factors.
Originally, interest surrounded the involvement of Bim in apoptosis since it was
discovered as a possible antagonistic binding partner for Bcl-2. The bim gene was found by
screening a bacteriophage lambda cDNA expression library constructed from a p53 deficient T
cell lymphoma line [46], with a recombinant Bcl-2 protein probe [47]. Additionally, the C.
elegans BH3-only homologue, EGL-1, was found to be essential for programmed cell death and
bound a Bcl-2 like protein, CED-9 [48]. In experiments with BimKO mice, these mice had
increased numbers of B and T cells, enlarged lymph nodes, and these cells survived longer in the
absence of essential cytokines [33]. These findings led others to evaluate the role of Bim in
cytokine withdrawal in vitro. For example, in pro-B cells, Bim protein levels increased upon IL3 deprivation [49]. However, healthy cells maintain basal Bim mRNA and protein levels, but at
such low concentrations that Bim was initially undetectable until cell numbers surpassed 10^7
[50]. Other studies have shown that Bim associates with mitochondrial Bcl-2 in healthy, resting
T cells and in cells undergoing apoptosis [51, 52].
Since basal levels of Bim protein were maintained in healthy cells, and sequestered under
non-apoptotic conditions, it was possible that regulation of Bim occurred transcriptionally. The
promoter of Bim is unique in that the region lies before the unencoded exon 1, lacking TATA or
CAAT boxes, but contains three RUNX sites and 1 SMAD site [53]. Bim is induced by many
extracellular stressors, including growth factor deprivation, and serum starvation [33, 54-56].
For example, in neuronal cells, NGF deprivation induced c-Jun-dependent upregulation of
BimEL mRNA and protein production [57]. Bim can be transcriptionally activated through
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alternative means.

In some healthy cells, PI3K-mediated activation of AKT, increases

phosphorylation of Foxo3a, inhibiting its nuclear translocation, thereby reducing Bim
transcription [58]. In pro-B cells withdrawn from IL-3, up-regulation of Bim mRNA synthesis
occurs through FKHR-L1 [49]. TGF-beta up-regulates RUNX1 expression, binds and regulates
Foxo3 levels, and up-regulates Bim transcription [53, 59]. TGF-beta can also inhibit ERK,
preventing phosphorylation-dependent degradation of Bim [60].

Interestingly, the IL-7Rα

promoter also contains a RUNX1 site, and up-regulation of IL-7Rα expression in T cells is, in
part, activated by RUNX1 [61]. Taken together, these studies indicate that regulation of the
transcription of Bim may be cell specific.
Alternative splicing of Bim results in over 18 isoforms, the three major isoforms being
BimEL, BimL, and BimS [47, 62, 63], with focus on canonical isoforms of Bim, with a lack of
study on physiological relevance, and protein products of the novel splice variants. Indeed, even
intron retention within BimEL cDNA can lead to increased BimL protein expression [64]. In
fact, in studies done with individually induced Bim proteins, an unintended side effect of upregulated BimL protein levels upon BimEL induction, can be seen [62, 65]. Recent studies have
concluded that BimEL and BimL are interchangeable for apoptotic function in homeostatic
hematopoiesis [66], but have not evaluated the individual isoforms in other context other than
degree of apoptosis upon treatment with immunosuppressors.

There exist non-apoptotic

isoforms of Bim as well. Overexpression of the splicing activator, SRSF1, which is upregulated
in breast cancers, promotes alternative splicing of non-apoptotic isoforms of Bim lacking the
BH3 domain. In fact, overexpression of one of these isoforms, Bim-γ1, resulted in reduced
apoptotic cell numbers compared to controls [67]. Alternative splicing also contributes to the
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phosphorylation state of Bim. Indeed, phosphorylation sites encoded by alternative splicing of
exon 3 contribute to increased BimL expression [68].
Bim activity is also regulated through phosphorylation. Two of the three major isoforms
of Bim (BimEL, BimL) contain phosphorylation sites, which garner control over its activity and
degradation. Currently, there is debate as to whether the phosphorylation of Bim, inhibits or
activates its activity.

Previous studies have shown that JNK and p38 MAPK mediated

phosphorylation of BimEL, increases apoptosis [68-71]. Additionally, the loss of IL-7 leads to
phosphorylation of BimEL and an increase in its pro-apoptotic activity, in T cells [52].
However, others have shown that phosphorylation by ERK [72-74] leads to ubiquitylation and
further, proteosomal degradation of BimEL.
In addition to regulation by alternative splicing mechanisms, and phosphorylation, Bim
can be regulated through its interaction with other proteins. Pro-apoptotic activities of Bim are
blocked through the inhibitory binding of pro-survival Bcl-2 [75]. However, in equal molarities,
BimL cannot overcome Bcl-2 protection [76]. In some healthy cells, BimL and BimEL are
bound to the dynein light chain [77] and upon encountering stress, such as UV light, BimL
detaches from LC8, and is released into the cytosol [78]. In fact, BimL can be found localized to
intracytoplasmic membranes independently of association with Bcl-2 [47].
In addition to mediating cell survival, IL-7 could regulate the maintenance of T cell
populations. Previous work has shown that Bim, a pro-apoptotic member of the Bcl-2 family,
participates in activated T cell death [39]. However, there is little study on the individual
isoforms produced through alternative splicing of Bim. In our own studies, we have confirmed
the involvement of Bim in apoptosis, and furthermore, the binding Bim to the dynein light chain

7

[77], but we have also discovered an anti-apoptotic role for Bim in the maintenance of
lysosomes.
IL-7 signaling in metabolism and growth
The mechanism by which IL-7 regulates the metabolism of certain T cell populations is
less known. Earlier work suggested that IL-7 promoted glucose uptake, independent of Stat5
activation [79], whereas others later found this function specifically mediated by Stat5 [80]. In
both cases, IL-7 induced up-regulation of glucose transporter, GLUT-1, trafficking to the cell
surface [79, 80].

However, activated T-cell glucose uptake is increased before GLUT-1

expression [81]. This led to our finding that HXKII, a glycolytic enzyme involved in glucose
metabolism, and the retention of intracellular glucose, was transcriptionally regulated by IL-7
[82].
In addition to the IL-7 signal transduction that occurs through Jaks activation, Stat5 can
be phosphorylated and activated by two Src kinases, Lck and Fyn [83, 84]. Other early work
suggested that Mitogen Activated Protein Kinase (MAPK) participated in the context of IL-7
signaling as well [85, 86]. Lck-mediated TCR signaling was shown to operate independently of,
or amplify IL-7 signaling to facilitate T cell proliferation [87]. Previously, we reported that an
IL-7 signal skewed T-cell subset proliferation, and trafficking [88, 89]. In fact, inhibition of Lck
modulated the IL-7 dose response of CD4 but not CD8 T-cells by regulating STAT5 activation
[88]. Concerning MAPKs, IL-7 could induce T cell proliferation without participation by ERK
[85] but p38 MAPK activation was required [86]. In contrast, we and others reported that IL-7
deprivation induced p38 MAPK and c-Jun N-terminal Kinase (JNK) activities and contributed to
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cell death [90, 91] as well as cell cycle arrest as a result of both the phosphorylation and
degradation of Cdc25A [89], and the up-regulation of the cyclin-dependent kinase inhibitor,
p27Kip1 [92]. Cdc25A, a phosphatase required for progression through the cell cycle, is also
activated through phosphorylation by Pim-1 [93], an IL-7 responsive kinase transcribed through
Stat5 [94].

Pim-1 contributes to the proliferation of T cells and can reconstitute thymic

cellularity in IL-7 and γc mutant mice [95]. In fact, in studies done in Pim TKO mice, reduced T
cell proliferation and response to growth factor signaling resulted [96]. However, Pim-1 can
negatively regulate the Jak/Stat pathway by phosphorylating and stabilizing the suppressor of
cytokine signaling, SOCS1 [97].
It is possible that growth and proliferation can be mediated by IL-7 in a Stat5
independent manner. Analysis of the HXKII promoter reveals putative binding sites for the
transcription factor complex, Activating Protein-1 (AP-1). Usually, AP-1 is composed of two or
more DNA-binding proteins, including those belonging to the Jun, Fos, Maf, and ATF protein
families [98].

Regulation of AP-1 is critical as its targets include genes involved in cell

proliferation, growth, transformation, DNA repair, and apoptosis [99]. The activity of AP-1 can
be regulated through phosphorylation of its components, with a feedback loop contributing to its
activation. For example, AP-1 initiates c-Jun transcription, and further enhancement through
rapid phosphorylation by JNK, perpetuates c-Jun activity and expression [100].

JNK also

activates another component of the AP-1 complex, JunD. JunD was initially described as a
negative regulator of proliferation [101, 102], although more recently, JunD was found to
stimulate anti-apoptotic protein expression in HTLV-1-infected T cells [103]. Taken together,
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these data suggest that IL-7 could alternatively activate HXKII through a mechanism other that
mediated by Stat5.
Recent Developments
Over the last few years, IL-7 has been considered for therapeutic development for a
diverse group of diseases. Animal studies have demonstrated that the administration of IL-7
stimulates reconstitution of immune cells in treatments such as stem cell transplants, and
chemotherapy [104-106]. Viral infection studies in mice have shown that administration of IL-7
increases the numbers of antigen-specific memory T cells [107]. Recently, a group has shown
adaptive regulatory T cells (Tregs), that normally repress the immune response, have the ability
to reverse diabetes, but require IL-7 for maintenance of population size [108]. Additionally,
administration of IL-7 has been used in an attempt to counteract T cell depletion in
immunodeficiencies.

While recombinant IL-7 (rhIL-7) did expand and diversify the TCR

repertoire of naïve T cells in pre-clinical trials [109], supraphysiological doses very different
from limited in vivo amounts were used. Additionally, IL-7 has the potential to be used to treat
HIV, idiopathic CD4 T cell lymphocytopaenia, and congenital immunodeficiency, as well as
supplementation after haematopoietic stem cell transplantation, or after chemotherapy for cancer
(reviewed in [110]). One challenge of using rhIL-7 is that this therapy has not been evaluated for
its impact upon functions of the individual cell subsets. Specifically, which cell activities are
stimulated, and how rhIL-7 contributes to their metabolism and maintenance of their population.
Recently, our studies have demonstrated that IL-7 dosing has an effect on the development of T
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cell subsets [88], indicating that there is a need to better understand the consequences of IL-7
signaling and its impact upon T cell gene expression.
The studies included here contribute to the understanding of the diverse and complex
pathways of metabolism and survival that the IL-7 signal directs in T cells. We attempt to fill in
the gaps in knowledge about how other signaling pathways, other than those transduced through
JAK/STAT, are involved in T cell growth, and how the multiple isoforms of Bim have separate
functions, particularly, in “housekeeping” and cell maintenance. Additionally, we explain how
IL-7 contributes to T cell metabolism through regulation of HXKII, eventual glucose
consumption, and cell scavenging to prevent premature death. Furthermore, we evaluate how
JNK, Bim, and other effectors of the IL-7 signaling pathway, can have various activities,
contrary to previous understanding. Without a further understanding of how IL-7 impacts T cell
survival and homeostasis, development of effective therapies cannot be achieved, nor the
consequences known by modulating IL-7 signaling.
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Figure 1. The IL-7 Receptor.
The heterodimeric IL-7 receptor is composed of two chains, the IL-7Rα chain (CD127) and the common γ
chain. The common γ chain is shared by receptors that recognize the IL-2 family of cytokines. Binding
of IL-7 to its receptor activates JAK1 and JAK3, after which self-phosphorylation increases their kinase
activities. JAK1 and 3 phosphorylate the tyrosine (Y) residue at site 499, creating a docking site for
STAT5a/b. The JAKs phosphorylate and activate STAT5, leading to STAT5 homodimerization, and
further, translocation to the nucleus to transcribe pro-survival genes.
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Figure 2. The Bcl-2 Family of Proteins.
The Bcl-2 family of proteins consists of pro-survival proteins, such as Bcl-2 and Bcl-XL, and proapoptotic members, which are either multidomain or BH3-only proteins. Pro-survival proteins bind
antagonistically to apoptotic proteins, and when an imbalance occurs, apoptosis results.
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CHAPTER 2: JUND/AP-1-MEDIATED GENE EXPRESSION PROMOTES
LYMPHOCYTE GROWTH DEPENDENT ON INTERLEUKIN-7 SIGNAL
TRANSDUCTION
Introduction
Interleukin-7 (IL-7) plays a major role in lymphocyte survival, development and
proliferation [2]. Because of its importance as a lymphocyte growth factor, IL-7 has potential use
as a therapeutic agent in cancer therapy [109], bone marrow transplantation [111] and treatment
of infectious diseases like sepsis [112] and HIV [113]. IL-7 is a 25 kDa protein that is not
produced by lymphocytes but was discovered as a product of a thymic stromal cell line [114].
Tissues that produce IL-7 include the generative lymphoid organs [115], [116]; however, the
regulation of IL-7 production remains unclear but could be induced in nonlymphoid tissues upon
infection [19]. The receptor for IL-7 (IL-7R), expressed by lymphocytes, consists of the IL-7Rα
chain and the common cytokine γ chain (γc) [117]. Upon binding of IL-7, the two receptor
chains heterodimerize and initiate signaling mediated through receptor-associated kinases, Janus
kinases, Jak1/Jak3, which phosphorylate and activate the transcription factor, STAT5a/b [2]. The
most recent biological information on IL-7 signal transduction focuses on the JAK/STAT
pathway, with scant new information on probable crosstalk with other signaling pathways.
Descriptions of the IL-7R interacting with Fyn or Lyn were published in the early 1990's
[118, 119], while other early work revealed aspects of Mitogen Activated Protein Kinase
(MAPK) signaling in the context of IL-7 [85, 86]. Lck-mediated T-cell receptor (TCR) signaling
was shown to both synergize and operate independently of IL-7 signaling to promote T-cell
proliferation [87]. We found that inhibition of Lck modulated the IL-7 dose response of CD4 but
not CD8 T-cells by regulating the activation of STAT5 [88]. In regards to the MAPKs, IL-7
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could induce T cell proliferation in the absence of ERK (Extracellular signal-Regulated Kinase)
activity [85] but required p38 MAPK [86]. In contrast, we and others reported that IL-7
withdrawal induced the activity of p38 MAPK and JNK (Jun N-terminal Kinase) and promoted
apoptosis [90, 91] as well as cell cycle arrest [89]. How MAPKs, like p38 MAPK and JNK, can
have both growth-promoting and apoptotic functions that are controlled by IL-7 remains
unknown.
One of the functions of the MAPK family is the post-translational regulation of
Activating Protein 1 (AP-1) transcription factors. AP-1 are dimeric transcription factors
composed of proteins with basic leucine zipper domains needed for dimer formation and DNAbinding [120]. The major subfamilies that form AP-1 are Jun (c-Jun, JunB and JunD) and Fos (cFos, FosB, Fra1 and Fra2). Activating Transcription Factor (ATF) proteins and Maf proteins can
also be components [121]. The potential for multiple combinations gives the AP-1 family its
specificity and capacity for a large repertoire of regulated-genes [122]. The activity of AP-1 is
mediated in part by ERK, JNK, or FRK (Fyn-Related Kinase) - each of these kinases
phosphorylates different substrates. Three distinct JNK gene families have been described:
JNK1, JNK2, and JNK3. JNK1 and 2 are ubiquitously expressed, while JNK3 is selectively
expressed in neuronal and cardiac tissues [123]. The Jun family is activated through
phosphorylation by JNKs, with c-Jun and JunD being recognized targets [124]. While c-Jun and
JunB are considered activating factors and expressed as early genes [125-127], JunD was first
described as a negative regulator of cell proliferation [101, 128, 129].
There exists a number of IL-7 functional targets [28]. To name a few, IL-7 promotes cell
survival through Bcl-2 upregulation and repression of Bax [29, 130, 131], Bim [44] or Bad [30].
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IL-7 drives proliferation through cell cycle regulators such as Cdc25A [89] and p27 kip [92]. IL7 also regulates glucose metabolism [80, 131], and this function is partially fulfilled through
transcriptional control of Hexokinase II (HXKII) [82]. How other signaling pathways augment
the JAK/STAT signal and contribute to T-cell growth is unknown. In this study, we investigated
the activity of the JNK pathway in IL-7- dependent T-cells and found that it involved the
activation of JunD-containing AP-1 complexes. JunD/AP-1 drove the expression of HXKII.
Using a bioinformatics approach, we discovered other JunD-regulated genes that included the
oncogene, Pim-1, which was induced by IL-7. The importance of these findings is the
demonstration that, in T-cells, JunD can modulate positive growth in response to IL-7, enhancing
the initial cytokine signal transduced by JAK/STAT.
Materials and Methods
Mice, Cell Lines and Culture Reagents
C57Bl/6 mice were purchased from Jackson Laboratory (Bar Harbor, Maine) and housed
at the University of Central Florida, Orlando, FL. Mice were used in accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the Institutional Animal Care and Use
Committee at the University of Central Florida (Assurance # A4135-01). All efforts were made
to minimize suffering. The IL-7 dependent T cell line, D1, was established from pro-T
lymphocytes isolated from a p53−/− mouse as previously described [28]. Since its establishment
in 1997, the D1 cell line has been used to study regulatory pathways controlled by IL-7 [22, 29,
30, 82, 89]. D1 T-cells were grown in RPMI 1640, 10% fetal bovine serum (FBS), 5%
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Penicillin/Streptomyocin (Fisher), 0.1% B-mercaptoethanol (Invitrogen) (complete medium) and
50 ng/mL IL-7 (Peprotech). Early passages of D1 cells were frozen as stocks and cells used at
less than 10 passages from stocks. Primary lymph node (LN) T cells were isolated from 8- to 12week-old C57Bl/6 mice as previously described [132]. To enrich for IL-7 dependent cells, we
used our published method of ex vivo expansion, culturing LN T cells with 150 ng/mL IL-7 for 5
days [132]. Reagents used as described in Figure Legends include: JNK inhibitor II
(Calbiochem, 20 µM), p38 MAPK inhibitor (Calbiochem, 20 µM), Wortmannin (Calbiochem, 5
nM), PD169316 (Calbiochem, 20 µM), MEK1/2 inhibitor (Calbiochem, 20 µM) and STAT5
inhibitor (Calbiochem, 50 µM).
Plasmids and Nucleofection for Transient Gene Expression
Generation of the chimeric IL-4 receptor/IL-7 receptor plasmids were previously
described [22] and pcDNASTAT5a-CA was a kind gift from Dr. Wenqing Li, NCI-Frederick. To
transiently express the plasmids, T-cells were “nucleofected” using the Murine T-cell
Nucleofection kit (Amaxa), following the manufacturer's protocol. Briefly, 1×106 D1 cells were
incubated with (4 µg) plasmid DNA in 100 µl of the mouse T-cell solution, and electroporated
with the specific program optimized for mouse T-cells. Nucleofected D1 cells were incubated in
the supplemented media with or without IL-7 for 4–8 hours prior to analysis. In D1 cells
nucleofection efficiency averaged approximately 40–50% expression of the target gene with
viabilities ranging 60–80%
Glucose Uptake Assay
Cells were incubated in glucose-free, serum-free RPMI 1640 supplemented with or
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without IL-7 for 1 hour. 2-Deoxy-D-[3H] glucose (2-DOG)(2 µCi/reaction) (Sigma) was added
for 3 min. Reactions were stopped by adding 250 µl of ice-cold 0.3 mM phloretin (Sigma). Cells
were then centrifuged through a cushion of 10% bovine serum albumin, and lysed with 0.1%
Triton X-100. Radioactivity was measured with scintillation counter (LS6500, Beckman
Coulter).
Real Time PCR
Ten million cells per experimental condition were re-suspended in 1 ml of TRIzol reagent
(Invitrogen). Total RNA was extracted from the cells using the reagent according to the
manufacturer's instructions. Each cDNA template was synthesized from total RNA by reverse
transcription with iScript cDNA Synthesis kit (BioRad) according to manufacturer's instructions.
Quantitative analysis of cDNA amplification was assessed by incorporation of SYBR Green
(ABI) into double-stranded DNA. Primer sets were used as follows: for mouse Pim-1: 5′-CCC
GAGCTATTGAAGTCTGA-3′, 5′-CTGTGCAGATGGATCTCA GA-3′ (sense and antisense,
respectively) [133], for mouse JunD: 5′-ATGGACACGCAGGAGCGCAT-3′ and 5′AGCAGCTGGCAGCCGCTGTT-3′ (sense and antisense, respectively) [134], for mouse
HXKII: 5′-CACTGGGTACTAAGGCTCAA-3′ and 3′-CGGAGTTGTTCTGCTTTGGA-5′ [82],
and

for

β-Actin:

5′-GAAATCGTGCGTGACATCAA

AG-3′

and

5′-

TGTAGTTTCATGGATGCCACAG-3′ (sense and antisense, respectively) [135]. Reactions
contained Fast SYBR Green Master mix (1×), β-Actin primers (50 nM), or Pim-1 or JunD
primers (100 nM), and 3–4 µg cDNA template. Thermal cycling conditions were as follows:
enzyme activation for 20 seconds at 95°C, followed by 40 cycles of 3 seconds at 95°C, and 30

18

seconds at 62°C at annealing and extension temperatures. All cDNA samples were processed
using the ABI Fast 7500 and analyzed using ABI Sequence Detection Software version 1.4. The
difference in mRNA expression was calculated as follows: fold change = 2−ΔΔCt, ΔΔCt is equal to
the change in ΔCt values over time after normalization to β-actin.
Detection of Proteins by Immunoblotting
For preparation of whole cell lysates, 20–25×106 D1 cells (per experimental sample)
were lysed using the Cell Lysis buffer (Cell Signaling) in the presence of protease and
phosphatase inhibitors (Roche). Lysates were immunoblotted for Pim-1 and JunD as described
below. For immunoblotting, whole cell lysate samples were run in 12% SDS-PAGE gels, and
proteins transferred to nitrocellulose membranes (Invitrogen) following manufacturers' protocols.
Membranes were washed and probed with primary antibodies (see below) and incubated with
horseradish peroxidase (HRP)-conjugated (Santa Cruz) or fluorescence-conjugated secondary
antibodies (LICOR). Signal was detected using either chemiluminescent substrate (SuperSignal
West Fempto; ThermoSci) or the LICOR Odyssey detection system. The primary antibodies used
in this study were as follows: a mouse monoclonal antibody against Pim-1 (Abcam), and rabbit
polyclonal antibodies against p38 (Santa Cruz Biotechnology), and JunD (Abcam).
JunD Inhibition by Small Interfering RNAs (siRNAs)
Four million D1 cells (per experimental condition) were treated with JUND1 SMART
pool siRNA (Dharmacon) and Accell delivery media (Dharmacon) supplemented with 1% FBS,
and IL-7 (50 ng/ml) for 52 hours. After 52 hours, cells were washed and re-plated in media
containing the siRNA alone, for 18 hours with or without IL-7. In addition, a subset of IL-7
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deprived cells was re-pulsed with the cytokine. SMART pool siRNA contains four sequence
variations of siRNAs to eliminate non-specific interactions. Non-targeting siRNA (NT siRNA)
and NT siRNA containing a FAM reporter, were used as controls and to determine delivery
efficiency, respectively.
Detection of JNK Activity
Whole cell lysates from 10×106 D1 cells (per experimental sample) were prepared using
the Kinase Extraction Buffer provided within the JNK kinase assay kit (KinaseSTAR JNK
Activity Assay Kit, BioVision) and assayed for protein concentration by absorbance at 280 nm
(Nanodrop 8000). To measure JNK activity, cell lysates were pre-cleared with Protein A/G
Sepharose beads (Santa Cruz) and then incubated with the kit provided JNK-specific antibody
and agarose beads to pull down JNK. Phospho-c-Jun was used as a substrate to measure JNK
activity following the manufacturer's protocol. Total JNK protein in lysates was measured using
a JNK-specific antibody (Cell Signaling) following the immunoblot procedure described above.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assay was performed using the ChIP-IT kit (Active Motif) according to
manufacturer's protocol. Briefly, 100×106 D1 cells were incubated overnight with or without IL7, and treated with 37% formaldehyde to crosslink protein to DNA. Cells were then treated with
the kit-provided lysis buffer supplemented with protease inhibitors and dounce homogenized.
Nuclear pellets were sonicated and pre-cleared using the Protein G beads provided within the kit.
Pre-cleared chromatin was incubated with anti-JunD antibody (Abcam) and immunoprecipitated
using Protein G beads according to the manufacturer's protocol. DNA was eluted and purified. To
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determine the DNA sequence to which JunD bound, PCR analysis of the DNA was performed
using AP-1 primers for the HXKII promoter sequence (Primer3 software): forward Primer
5′GGGCTCTAGGCGCTGATT3′ and reverse Primer: 5′GGAGTTGGTGCAACAATGTG3′.
PCR products were analyzed by non-denaturing agarose gel (1%) electrophoresis.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extraction and EMSA were performed according to the method described by
Jaganathan et al. [136] and a modified Dignam protocol [137]. Briefly, 60×106 cells were washed
and cell lysates prepared with hypotonic buffer (20 mM HEPES (pH 7.9), 1 mM EDTA, 1 mM
EGTA, 1 mM Na3VO4, 1 mM Na4P2O7, 0.5 mM PMSF, 0.1 mM aprotinin, 1 mM leupeptin, 1
mM antipain, and 1 mM DTT). NP-40 was added to a final concentration of 0.2% and the
solution was centrifuged. The supernatants were retained as cytosolic controls and the nuclear
pellets lysed with hypertonic extraction buffer (20 mM HEPES (pH 7.9), 0.42 M NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, 20 mM NaF, 20% glycerol, 1 mM Na3VO4, 1 mM Na4P2O7,
0.5 mM PMSF, 0.1 mM aprotinin, 1 mM leupeptin, 1 mM antipain). The nuclear fractions were
then recovered by centrifugation. Transcription factors bound to specific DNA sequences were
examined by EMSA. Normalized extracts, containing 3–8 µg of total protein, were incubated
with a double-stranded
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P-radiolabeled AP-1 oligonucleotide probe (Santa Cruz) prepared by

radiolabeling the AP-1 probe with [α32P]dCTP (3000 Ci/mmol) and [α32P]dATP (3000 Ci/mmol).
Protein-DNA complexes were resolved by non-denaturing polyacrylamide gel electrophoresis
(PAGE) and detected by autoradiography. To establish the specificity of the AP-1 probe,
unlabeled AP-1 oligonucleotides or mutant AP-1 nucleotides (Santa Cruz) were incubated with
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nuclear extracts for 15 min before incubation with radiolabeled probes. To identify components
of the AP-1 transcription factor in the DNA–protein complex shown by EMSA, we used proteinspecific supershift antibodies, c-Fos, c-Jun and JunD (Active Motif), to detect the formation of a
supershift DNA–protein complex. These antibodies were incubated with the nuclear extracts for
30 min at room temperature before incubation with radiolabeled probe.
Analysis of JunD ChIP-seq Data
The JunD ChIP-seq (chromatin immunoprecipitation followed by high throughput
parallel sequencing) data for three cell lines, GM12878, Helas3, and K562, was downloaded
from http://hgdownload.cse.ucsc.edu/goldenPat h/hg18/encode DCC/wgEncodeYaleChIPseq/.
Narrow peaks provided by this website were used as the binding regions of JunD. These narrow
peaks are regions enriched with JunD binding segments in ChIP-seq experiments, and are
selected with a false discovery rate [138] of 0.001. In total, 12958, 45893, and 1500 JunD
binding regions were obtained from the GM12878, Helas3, and K562 cell lines, respectively.
These JunD binding regions were compared with all annotated refseq genes in the human
genome. By assuming that the genes closest to the above binding regions were target genes of
JunD, we obtained 6754, 15577, and 1643 target genes in the above three cell lines, respectively.
For example, we obtained 1643 target genes in the K562 cell line with only 1500 binding regions
because some binding regions were located in multiple annotated genes. To understand the
function of these target genes, we performed gene ontology analysis by using the GOTermFinder
software [139]. Results are found in supplemental files, Figure S2 and Data S1. A previous
cDNA array, using IL-7 dependent D1 cells [28], identified 179 genes that were immediate
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responders to a two hour pulse with IL-7. We found that 116 out of the 179 IL-7-responsive
genes were target genes of JunD in the three cell lines. However, 108 out of the 116 genes are not
annotated.
Proliferation Assay for Primary Lymphocytes
Five to ten million primary LN T-cells, enriched by 5 day culture with IL-7 and treated
with control or JunD siRNA as described above, were examined for proliferative capacity.
Viability of cultured cells was determined based on cell shrinkage and granularity by gating on
FSC/SSC parameters acquired by flow cytometry (Accuri C6 Flow Cytometer). IL-7-cultured
primary T-cells treated with siRNAs were pulsed with 10 µM BrdU for 48 hours. DNA synthesis
was evaluated through BrdU incorporation, using a PE-tagged, anti-BrdU antibody for detection
of DNA content with a commercially available kit according to manufacturer's protocol (BD
Biosciences). Surface expression of CD4 and CD8 on the primary T cells were assessed by flow
cytometry using the following conjugated antibodies: PerCP-anti-CD4 (clone RM4-5), and
PerCP-anti-CD8 (clone 53-6.7) (BD Biosciences). Cells were incubated with antibodies for 20
min on ice, washed in RPMI+10% FBS, prior to BrdU analysis, and analyzed by flow cytometry
on a C6 flow cytometer (Accuri).
Statistics
Statistical analysis and significance was determined using Prism 5 (Graphpad) for
Windows, Version 5.02.
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Results

Previously, using an IL-7 dependent T-cell line, D1, and primary T-cells, we reported that
HXKII gene expression was regulated by an IL-7 signal [82]. However, we found that inhibition
of STAT5 did not prevent the expression of HXKII in response to IL-7 (Fig. S1). To demonstrate
that a STAT5-independent, but still an IL-7 dependent signal, controlled HXKII gene expression,
we nucleofected D1 cells with a chimeric IL-4/IL-7 wild-type receptor or with a chimeric IL4/IL-7 receptor bearing a mutation in the STAT5 binding site, Y449. Normally, when Y449 is
phosphorylated it binds STAT5; therefore mutation of this site would prevent STAT5 activation.
D1 cells, nucleofected with the chimeric receptors, were cultured with human IL-4. Gene
expression of HXKII was measured by quantitative PCR and glucose uptake was measured by 2DOG uptake. We found that the IL-4-induced HXKII gene expression and glucose uptake in
nucleofected cells was not affected by the Y449 mutation and that cells were comparable to those
incubated with IL-7, suggesting that these events were STAT5-independent [140]. Examination
of the mouse HXKII promoter region showed that the proximal promoter region contained most
of the transcription factors binding motifs that regulate HXKII expression [141]. Some of the
recognized factors included SP-1, NF-Y, CREB, Glucose binding site, and the AP-1 complex. To
study this, we examined the activity of the MAPK pathway and induction of AP-1 transcription
factors in response to IL-7.
JunD/AP-1 complexes are activated upon IL-7 stimulation through the JNK Pathway
A limited number of studies showed that IL-7 withdrawal up-regulated p38 MAPK [91]
and JNK [90], and that ERK signaling was dispensable in IL-7 dependent T-cells [85]. Because
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of the importance of JNK in AP-1 activation [120], we examined JNK activity in response to IL7. Previously, we and others established that D1 cells express all the known components of the
IL-7 signaling pathway and are representative of the primary T-cell response to IL-7 [30, 45, 52,
82, 89, 92]. Because of this and the fact that primary T-cell subsets are not equally responsive to
IL-7 [88, 132], in the current study we used D1 cells, which uniformly respond to the cytokine,
to study the functional outcomes of IL-7 signal transduction. Our goal was to identify novel
molecular events driving the lymphoproliferative activity of IL-7. A JNK activity assay was
performed that involved immunoprecipitation of the kinase from whole cell lysates and detection
of the phosphorylated c-Jun substrate as a read out for kinase activity. As shown in the
immunoblot for phosphorylated c-Jun substrate in Figure 3, D1 cells incubated with IL-7 had
higher levels of JNK activity than those deprived of IL-7 (Fig. 3). In IL-7-deprived D1 cells,
JNK activity was initially observed through 6 hours of cytokine withdrawal and was
undetectable after 18 hours of cytokine withdrawal. As control for protein input, JNK levels were
detected in lysates prior to immunoprecipitation. These results support that JNK activation is a
part of the IL-7 signaling pathway.
Since JNK is known to regulate the components involved in AP-1 activation, a gel shift
assay was performed to determine whether IL-7 induced AP-1 DNA-binding activity. An
oligonucleotide probe containing the AP-1 DNA-binding consensus site was incubated with
nuclear extracts from D1 cells grown with or without IL-7 for 18 hours. EMSA results revealed
that more AP-1 bound to DNA in D1 cells incubated with IL-7 [140]. This suggested that IL-7
induced the formation of AP-1 complexes that bound to the consensus DNA sequence. To
confirm specific binding of the protein to the AP-1 probe, a competition assay with excess cold
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AP-1 probe (unlabeled) as well as with a mutant AP-1 probe was performed. Addition of cold
AP-1 probe effectively reduced binding of protein to the radiolabeled AP-1 probe, while addition
of mutant AP-1 probe had little effect [140]. To identify the components that formed the IL-7induced AP-1 complex, nuclear extracts, made from D1 cells grown with IL-7, were coincubated with supershift-specific antibodies against c-Fos, c-Jun and JunD, and added to the
AP-1 radiolabeled DNA probe. We found that the c-Fos and c-Jun antibodies did not produce a
supershift or impede protein binding to DNA, whereas the JunD antibody caused steric
hindrance, preventing protein binding to the AP-1 DNA probe [140]. This illustrates that IL-7
stimulation resulted in an AP-1 complex containing JunD.
To determine whether the JNK pathway was involved in synthesis and activation of JunD
in response to IL-7, we examined, by quantitative PCR, JunD gene expression levels in response
to IL-7 and in the presence of JNK (and, as control, p38 MAPK) pharmacological inhibitors.
Note that doses of inhibitors used were experimentally determined. D1 cells were grown with or
without IL-7 for 18 hours, and, to a separate population of cytokine-deprived cells, IL-7 was
added back for 2 hours to induce expression of IL-7-dependent gene products. Loss of IL-7
caused a decrease in the gene expression of JunD that was restored upon a two hour re-addition
of IL-7 (Fig. 4A). This IL-7-driven increase in JunD mRNA was inhibited by treatment with the
JNK but not the p38 MAPK inhibitor (Fig. 4A). To confirm this result, protein lysates from
similarly treated cells revealed that JunD protein decreased in the absence of IL-7 and increased
upon IL-7 re-addition (Fig. 4B) in the manner observed for the mRNA levels (Fig. 4A).
Inhibition of JNK caused a reduction in protein levels of JunD (Fig. 4B); a result consistent with
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the gene expression data (Fig. 4A) and the decrease in JNK activity noted after IL-7 withdrawal
(Fig. 3).
IL-7-dependent JNK activity drives glucose uptake through the synthesis of HXKII
To investigate a functional consequence of JNK activity, D1 cells were deprived of IL-7
for 18 hours and IL-7 added back to the culture with the addition of either PD169316, (p38
MAPK/JNK inhibitor), MEK1/2 inhibitor, or wortmannin (PI3K (Phosphoinositide 3-kinase)
inhibitor). As an indicator of cell metabolism, glucose uptake was measured using 2-DOG [82].
Figure 5A showed decreased glucose uptake in D1 cells that were stimulated with IL-7 and
incubated with PD169316, an inhibitor of the p38/JNK pathway, but not with inhibitors of the
MEK1/ERK pathway or the PI3K pathway. To differentiate between the p38 MAPK and JNK
pathways, glucose uptake was then measured in IL-7-stimulated D1 cells cultured with specific
inhibitors for JNK or p38 MAPK. Figure 5B demonstrates that D1 cells incubated with a JNK
inhibitor, but not a p38 MAPK inhibitor, had decreased glucose uptake upon IL-7 addition. To
show that, upon IL-7 stimulation, JunD/AP-1 complexes mediated the uptake of glucose, D1
cells were treated with JunD siRNA and assayed for the uptake of 2-DOG. The efficacy of
siRNA knockdown of JunD mRNA (~60%) and protein (~50%) are shown in later figures.
Inhibition of JunD reduced the uptake of glucose in IL-7-stimulated D1 cells to levels
approaching those observed in the cells cultured without IL-7 (Fig. 5C). Note that background
levels of 2-DOG uptake are indicated by the IL-7 deprived controls and are the point of
comparison for the other experimental samples. These results indicate that JNK and JunD/AP-1
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complexes were in part responsible for regulating the activity of factors that promoted glucose
uptake upon IL-7 stimulation.
In our previous study, we reported that HXKII gene expression increased after two hours
of IL-7 re-addition to deprived cells [82]. We also found that a STAT5-independent mechanism
with driving the synthesis of HXKII [140]. Since the gene expression of JunD was dependent
upon JNK and IL-7 (Fig. 5A), it was possible that the increase of HXKII gene expression that
followed IL-7 re-addition was also associated with the activity of JNK. Therefore, the synthesis
of HXKII was evaluated in D1 cells stimulated with IL-7 and treated with a JNK inhibitor.
Quantitative PCR results demonstrated that HXKII synthesis was reduced by about 60%
compared to vehicle control upon treatment with JNK inhibitor (Fig. 6A). D1 cells incubated
with the p38 MAPK inhibitor showed little effect (Fig. 6A). This data confirmed that the IL-7driven increase in HXKII gene expression is likely mediated by JNK. To establish a role for
JunD-containing AP-1 complexes in HXKII gene expression, D1 cells were stimulated with IL-7
and treated with JunD siRNA. Shown in Figure 6B is a representative experiment in which loss
of JunD reduced the IL-7-driven expression of HXKII. A graph alongside shows that treatment
with JunD siRNA reduced JunD mRNA levels by approximately 60% as compared to the nontargeting control siRNA. Hence, JunD/AP-1 complexes were contributing to the synthesis of
HXKII in response to IL-7.
The binding of JunD/AP-1 complexes to the AP-1 site on the HXKII promoter was
examined to validate our conclusions. To this end, a chromatin immunoprecipitation assay
(ChIP) was performed. Nuclear lysates of D1 cells cultured with and without IL-7 for 18 hours
were incubated with JunD antibody to immunoprecipitate JunD-bound DNA. Quantitative PCR

28

was then performed, using primers specific to the AP-1 region on the HXKII promoter to amplify
a DNA sequence of approximately 150 base pairs. We reported the cycle threshold (Ct) values of
cells cultured with (31.219) and without (37.374) IL-7, indicating that amplification of the
HXKII promoter DNA, immunoprecipitated with the JunD antibody, from IL-7-cultured cells,
occurred 6 cycles faster than from IL-7 deprived cells and was thus significantly more abundant.
Endpoint DNA from the amplification reactions was run on a non-denaturing agarose gel, and
visualized using ethidium bromide staining, to demonstrate that more HXKII promoter DNA was
amplified from samples of D1 cells cultured with IL-7. Controls for the reaction are the total
DNA inputs, showing equivalent amounts of starting materials. This representative experiment
confirms that JunD-containing AP-1 complexes bound to the AP-1 site within the HXKII
promoter region in an IL-7 dependent manner.
Bioinformatics Approach Reveals Novel IL-7 Induced Genes Induced by AP-1/JunD
To identity novel IL-7-regulated genes whose synthesis was driven by JunD/AP-1
complexes, we performed a bioinformatics analysis. Previously, we identified a number of genes
whose expression was induced upon IL-7 stimulation or deprivation [28]. A comparison of these
genes with potential JunD-targeted genes (identified in a bioinformatics screen, see Methods and
[140]) yielded a number of targets containing putative JunD binding sites that were potentially
IL-7-responsive. The diagram, shown in Figure 7, organizes the information by function. Of the
three cell lines characterized, gene functions were separated into suppressive (red) or supportive
actions (green). Many of the gene products identified were involved in signal transduction,
survival or adhesion (Fig. 7). Among these, JunD emerged as a self-regulated and IL-7 dependent
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gene (Fig. 7). Suppressive genes were generally involved in blocking inflammatory processes
(Fig. 7). The cell line databases assessed for potential JunD target genes were also evaluated for
functional homology, whether inhibitory or stimulatory. The most significant gene ontology
terms, according to cell line, are listed in order by P-value and are provided as Data S1. Gene
ontology ID (GO), significance by p-value, and the number of genes annotated with that term are
found in supplemental files. Also included under each cell line are the number of annotated target
genes and the number of target genes for the specific cell line. This approach revealed that a
variety of functions can be ascribed to JunD-mediated transcription, specifically, regulation of
signal transduction, cell cycling and cellular metabolic processes. Of those genes, ones initiated
early in the IL-7 signaling cascade, which could drive additional growth pathways, were of
interest for study.
Pim1 is an IL-7-Inducible Gene Product through the Activity of AP-1/JunD
One of the genes that emerged from the bioinformatics analysis as a JunD target and IL-7
dependent was the proto-oncogene, Pim-1. Hence, Pim-1 was chosen for evaluation to validate
the bioinformatics approach and provide insight on a novel aspect of the IL-7 signal. The
repetitive blot in Figure 8A revealed detectable levels of Pim-1 protein in D1 cells grown
continuously with IL-7 for 18–24 hours, while withdrawal of IL-7 for 2–24 hours caused a
decline in Pim-1. Next, we examined the effect of JNK inhibition upon Pim-1 protein levels in
D1 cells grown with or re-stimulated with the cytokine. Our data in Figure 8B indicates that the
basal levels of Pim-1 protein expressed in D1 cells, continually growing in IL-7, were only
slightly decreased by inhibition of JNK; however, the increased amounts of Pim-1 that were
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induced upon re-stimulation with IL-7 for 2 or 4 hours after deprivation were almost completely
inhibited by blocking JNK activity. These results suggest that basal levels of Pim-1 were in part
JNK-dependent, but that induction of Pim-1 protein upon IL-7 re-addition was almost
completely dependent upon JNK signaling (Fig. 8B). To establish that JunD/AP-1 factors were
transducing the JNK signal that induced Pim1, we repeated the experiment using JunD siRNA
and observed a measureable decrease in Pim-1 protein induction after IL-7 re-addition (Fig. 8C)
when JunD expression was impaired. Levels of JunD protein in these cells are shown for
comparison.
These studies were followed by examining Pim-1 gene expression in response to either
JNK or AP-1/JunD inhibition. In Figure 9A, re-addition of IL-7 caused an increase in Pim1
mRNA supporting that increase previously detected by protein assay (Fig. 8B). Inhibition of JNK
decreased the levels of Pim-1 mRNA in D1 cells stimulated with IL-7, while little or no effect
was observed in D1 cells continually grown in IL-7. Likewise, as observed for protein levels of
Pim-1, inhibition of JunD with siRNA decreased Pim-1 gene expression in cells re-stimulated
with IL-7 after deprivation (Fig. 9B).
Proliferation of Primary Lymphocytes in Response to IL-7 Depends on JunD Activity
Our studies with the D1 cell line revealed the specifics of the IL-7 signaling pathway
from activation of JNK through induction of the JunD/AP-1 transcription factors and increased
gene expression of HXKII and Pim-1. The expected outcome of IL-7 signal transduction through
this pathway would be T-cell proliferation. To examine this, we used our ex vivo expansion
protocol [132] to isolate IL-7-dependent primary T-cells. This expansion method is needed
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because freshly isolated lymphocytes contain only a small number of T-cells that proliferate in
response to IL-7 (~10–20%, Khaled, unpublished data). To confirm the results observed with D1
cells, that JunD and Pim1 expression was dependent on the JNK pathway, we treated IL-7
stimulated T-cells with a JNK inhibitor and assessed the effect upon protein levels of JunD and
Pim-1. Results in Figure 10A show that JNK inhibition resulted in decreased JunD and Pim-1
proteins (34% and 64% respectively), substantiating the data from D1 cells. Note that primary Tcells under IL-7-deprived conditions cannot be evaluated because these fail to expand and die in
culture. To evaluate IL-7-driven proliferation, we measured the incorporation of BrdU in CD4
and CD8 T-cells. As shown in Figure 10B, continuous culture with IL-7 caused CD8 T-cell
expansion (16%) to occur more rapidly as compared to CD4 T-cells (2%) – an observation
previously published [88]. The addition of JunD siRNA had a modest inhibitory effect (Fig.
10B). However, examining the proliferation of CD4 and CD8 T-cells, re-stimulated with IL-7,
revealed that JunD inhibition reduced IL-7 driven growth by more than 60% - more so for the
actively dividing CD8 T-cells (from 13% to 5%) (Fig. 10C). These results suggest that IL-7
signaling promotes T-cell proliferation in part through JunD-mediated transcription of gene
products such as Pim-1 or HXKII.
In summary, we have shown that IL-7 promotes growth signals through other
transcriptional components in addition to STAT5. We found that the JunD/AP-1 transcription
factors are activated in response to JNK and drive the synthesis of at least two essential
mediators of lymphocyte growth, HXKII and Pim-1, in response to IL-7 stimulation. These
results establish a novel approach employing bioinformatics to discover new transducers of the
IL-7 metabolic and proliferative signals.
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Figure 3. IL-7 signaling induces JNK activity.
JNK activity was determined by the capacity to phosphorylate the substrate, c-Jun. JNK was immunoprecipitated
from whole cell lysates prepared from D1 cells cultured in the presence or absence of IL-7 for the times indicated.
Pre-immunoprecipitation levels of JNK (input) in lysates are shown. Results are representative of three or more
independent experiments.
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Figure 4. JNK activity promotes JunD expression.
(A) Quantitative PCR evaluation of JunD expression in the IL-7 dependent T-cell line, D1. Cells were continuously
cultured with IL-7 or without IL-7 for 18 hours, or withdrawn from IL-7 (18 hours) and then re-stimulated for two
hours (IL-7 Re-addition). Re-stimulated cells were untreated, treated with DMSO (Vehicle Control), 20 µM JNK
inhibitor (JNK inhibitor), or 20 µM p38 MAPK (p38) inhibitor. (***) indicates P < 0.0001. (B) Western blot
analysis of JunD protein and p38 MAPK protein content, as loading control, of whole cell lysates from D1 cells
cultured as stated above. Relative JunD protein indicates JunD protein levels normalized to p38 MAPK (loading
control) and compared relative to the untreated, re-stimulated sample. Results (A, B) are representative of four
independent experiments (values in graphs are mean ± SD).
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Figure 5. A functional consequence of JNK/JunD signaling is the IL-7 dependent uptake of glucose.
D1 cells continuously cultured with or without IL-7 for 18 hours, or withdrawn (18 hours) and then stimulated with
IL-7 for four hours (IL-7 Re-addition), were untreated or treated with DMSO (Vehicle Control), 20 µM MAPK
inhibitor, 20 µM PD169316, 20 µM MEK1/2 inhibitor or 5 nM PI3K inhibitor, wortmannin. Glucose uptake was
assessed by measuring the accumulation of radiolabeled 2-DOG as stated in Methods. (*) indicates P = 0.0348. (B)
D1 cells were treated similarly as those in (A) except that cells were pulsed for two hours and specific inhibitors for
JNK (20 µM) or p38 MAPK (20 µM) were used. (*) indicates P = 0.0342. (C) D1 cells were cultured with or
without IL-7 after introduction of non-specific control (NT) or JunD siRNA as described in Methods. Glucose
uptake was assessed as above by measuring the accumulation of radiolabeled 2-DOG. (*) indicates P = 0.0320.
Results (A, B, and C) are representative of three or more experiments performed (values in graphs are mean ± SD).
Glucose experiments were performed by Mounir Chehtane, and analysis and interpretation by Shannon Ruppert.
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Figure 6. HXKII gene expression is dependent upon JNK/JunD signaling.
(A) HXKII gene expression in the IL-7 dependent T cell line, D1, was measured by quantitative PCR as described in
Methods. Cells were cultured with or without IL-7, or after an IL-7 pulse for 2 hours (IL-7 Re-Addition), in
presence of a vehicle control, 20 µM JNK inhibitor, or 20 µM p38 inhibitor. RQ (Fold change) = 2-ΔΔCt. (***)
indicates P < 0.001. (B) HXKII gene expression in D1 cells cultured with or without IL-7 and the non-targeting
control (NT) or JunD siRNA, as described in Methods, was measured as described above. (*) indicates P = 0.0254.
Efficacy of JunD siRNA upon JunD mRNA levels (right panel) was established through measuring total JunD gene
expression by quantitative PCR. (*) indicates P = 0.0336. RQ (Fold change) = 2-ΔΔCt. Results are representative of
three experiments performed in triplicate (values in graphs are mean ± SD). HXKII gene expression experiments
were performed by Mounir Chehtane, and JunD gene expression experiments, and analysis and interpretation of
each were completed by Shannon Ruppert.
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Figure 7. Bioinformatics evaluation of potential IL-7 dependent genes transduced through JunD.
Three cell lines (GM12878, Helas3, and K562) were evaluated for genes containing putative JunD binding sites that
are potentially IL-7-responsive, as described in Methods. Gene functions were determined using gene ontology
analysis as described in Methods, and were separated into suppressive (red) or supportive actions (green).
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Figure 8. Pim-1 protein is dependent on IL-7 and JNK/JunD.
(A) Immunoblot analysis of Pim-1 was performed. Whole cell lysates were prepared from D1 cells cultured in the
presence or absence of IL-7 for the indicated time points. p38 MAPK was measured as a loading control. (B)
Immunoblot analysis of Pim-1 was performed. Whole cell lysates were prepared from D1 cells cultured in the
presence or absence of IL-7 and/or with JNK inhibitor (20 µM), or 2-4 hour IL-7 stimulation after 18 hour
deprivation, alone, or with 20 µM JNK inhibitor. p38 MAPK was used as a loading control. (C) Whole cell lysates
of D1 cells were cultured for 52 hours with IL-7 in the presence of non-targeting control (NT) or JunD siRNA, then
cells were withdrawn from IL-7 for 18 hours as described in Methods. A separate group was also deprived of IL-7,
and then re-stimulated with IL-7 for two hours in the presence of either siRNA (Re-addition). Whole cell lysates
were subjected to SDS-PAGE and immunoblotted for Pim-1, JunD, and p38 as loading control. Tables indicate
relative amounts of protein normalized to p38 content and shown relative to the IL-7 re-addition sample. Results are
representative of three experiments performed.
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Figure 9. IL-7 inducible Pim-1 gene expression is dependent on JNK/JunD.
(A) Pim-1 gene expression in the IL-7 dependent T cell line, D1, was measured by quantitative PCR as described in
Methods. D1 cells were cultured with or without IL-7 (+/- IL-7), in the presence of a vehicle control (Vehicle) or 20
µM JNK inhibitor (JNK Inh). In some samples, after an 18 hour deprivation, IL-7 was added back to the culture for
2 hours in the presence of a vehicle control (IL-7 Re-addition, Vehicle) or 20 µM JNK inhibitor (IL-7 Re-addition,
JNK Inh). (*) indicates P = 0.0104. (B) Quantitative PCR of Pim-1 gene expression was performed using D1 cells
cultured for 52 hours with and 18 hours without IL-7 in the presence of non-targeting control (NT) or JunD siRNA.
A separate group was also deprived of IL-7, and then re-stimulated with IL-7 for two hours in the presence of either
siRNA (IL-7 Re-addition). RQ (Fold change in gene expression normalized to β-actin) = 2-ΔΔCt. Results are
representative of three experiments performed in triplicate (values in graphs are mean ± SD). (*) indicates P =
0.0140.
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Figure 10. Inhibition of JunD prevents IL-7 induced proliferation of primary lymphocytes.
(A, B) Proliferation was measured by BrdU incorporation. Lymph node T cells were isolated from WT C57Bl/6
mice, cultured continuously with 150 ng/ml of IL-7 for 7 days (A), or for 5 days, then deprived from IL-7 for 18
hours, and stimulated for 24 hours (B) as described in Methods, Cells were assessed for BrdU incorporation and
surface expression of CD4 and CD8 as determined by flow cytometric analysis of BrdU-PE and CD4- or CD8PerCp fluorescence. Dot blots show percentages representing the population of cells that are non-proliferating
(BrdU negative), proliferating (BrdU positive), and CD4+ or CD8+ as indicated by the quadrants. Quadrants were
established using controls. Gating was performed to remove autofluorescent cells. Results are representative of
duplicate samples.
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Discussion
Our results suggest that IL-7 in part contributes to the metabolism and growth of T-cells
by promoting HXKII and Pim-1 gene expression through the JNK activation of JunD/AP-1. This
conclusion was reached by finding that JNK was active in response to IL-7, and that IL-7
induced the binding of AP-1 transcription factors, containing JunD, to DNA sequences such as
the HXKII promoter. Using a bioinformatics approach to discover previously unrecognized JunD
gene targets that were IL-7-responsive, we identified Pim-1. Confirmation that Pim-1 expression
was IL-7- and JunD-dependent, validated the bioinformatics results. Physiological relevance of
our findings was established when inhibition of JNK in primary lymphocytes decreased the
levels of Pim-1 and JunD and inhibition of JunD prevented the proliferation of CD8 T-cells
stimulated with IL-7. This work achieves the goal of demonstrating that other regulators of gene
expression, in addition to the JAK/STAT5 pathway, can respond to the IL-7 signal in T-cells and
indicates that a bioinformatics approach can be used to discover novel IL-7 signal transducers.
To support T-cell growth, IL-7 signaling leads to the activation of transcription factors,
such as STAT5. STAT5 can mediate T-cell survival by inducing anti-apoptotic proteins of Bcl-2
family [142, 143]. STAT5 also promotes glucose metabolism by enabling GLUT1 trafficking to
the cell surface [80]. However, we found that the IL-7-mediated increase of HXKII gene
expression used a STAT5 independent mechanism to regulate glucose uptake in T-cells. We
identified JunD-containing AP-1 complexes as key factors that controlled the synthesis of HXKII
in response to IL-7. Pim-1 is also a recognized gene transcribed by STAT5 [94] and a possible
JunD-target. We found that T-cells deprived and then re-stimulated with IL-7, which mimics the
in vivo conditions in which T-cells encounter IL-7, immediately increased Pim-1 levels in a
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JunD/AP-1 dependent manner. This is consistent with the proliferative function of Pim-1, since
it phosphorylates and induces the activity of proteins involved in cell cycling, including Cdc25A
[93] and Skp2 [144]. Our conclusions are supported by the fact that Pim-1 is an effector of the
IL-7 signaling pathway, as its expression reconstituted thymic cellularity in IL-7 deficient mice
[95], and that Pim-1, 2 and 3 are required for proliferation of peripheral T-cells [96].
JunD was initially described as a negative regulator of proliferation. Early studies showed
that over expression of JunD in immortalized fibroblasts increased the numbers of cells in the
G0/G1 phase of the cell cycle, promoting growth arrest [101].

JunD also suppressed

transformation by Ras [101]. Immortalized cells lacking JunD had higher levels of cyclins and
increased proliferation, but also were more sensitive to death-inducing agents, suggesting that
JunD could have both negative and positive effects upon cell growth [145, 146]. Concerning the
latter activity, JNK and JunD were shown to work with NF-kB to increase the expression of the
caspase inhibitor, cIAP-2 [146]. While these studies were performed using immortalized cells
and fibroblasts, the evaluation of JunD activity in lymphocytes revealed different results and
demonstrated that JunD activity can be cell specific. JunD over expression did not protect
lymphocytes from apoptosis and caused reduced growth and activation, while JunD−/− T-cells
hyperproliferated upon stimulation [147]. These findings seemed in apparent conflict with our
data that HXKII, a key enzyme in the glycolytic pathway, was a JunD target gene. To explain
this, we performed a bioinformatics evaluation of potential JunD-regulated genes and found that
many critical effectors of cell signaling and growth (like Pim-1), survival (like Bcl-2), and
metabolism were possible JunD targets. Further, we found that inhibition of JunD impaired the
proliferation of T-cells in response to IL-7. While, JunD remains a negative regulator of growth
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in many cells, like intestinal epithelial cells in which JunD repressed gene expression of cyclin
dependent kinase 4 (CDK4) [102], in IL-7-pulsed T-cells, as shown in our studies, JunD
promotes the expression of essential growth effectors.
Regulation of JunD gene expression is not typical of other AP-1 components. Contrary
to results with other AP-1 proteins, JunD protein levels were detected in quiescent immortalized
cells; JunD protein then initially declined upon serum stimulation and later steadily increased
[101]. Coupled to the constitutive activity of the JunD promoter, this suggests that JunD may be
controlled by different post-transcriptional or post-translational mechanisms. As example, the
JunD transcript is intronless, is G/C rich, has a long 5′ untranslated region (UTR) and produces
two isoforms, a full-length and truncated form (reviewed in [148]). Moreover, the presence of a
unique post-transcriptional control element (PCE) and the potential interaction with RNA
helicase A (RHA) suggests that JunD could be efficiently translated under the right growth
conditions [149]. Post-translational modifications also contribute to the activity of JunD in
different cellular environments. JunD is poorly ubiquitinated and has a long half-life [150]. The
JunD transcript is also positively regulated by JNK activity [151], as we have shown in the IL-7dependent D1 cells. In fact, JNK could stimulate an auto-regulatory loop that controls the gene
expression of JunD.
In summary, JunD emerges as an important transducer of the IL-7 signal in T-cells and,
along with the JAK/STAT pathway, could promote gene expression to drive survival and growth
when cells are stimulated with IL-7. The importance of this conclusion is appreciated when
considering that T-cells normally exist in an IL-7-limited environment (with picograms levels of
the cytokine normally detected in serum [152]). To be stimulated, T-cells must traffic to IL-7-
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containing tissues. When a T-cell receives an lL-7 signal, the JNK/JunD pathway may function
to enhance the JAK/STAT mechanism and induce expression of genes like HXKII and Pim-1 as
a rapid response to the initial growth signal. Because the therapeutic use of IL-7 involves
application of superphysiological dosing of the cytokine that is very different from the in vivo
state of limited IL-7 availability, there is a need to better understand the consequences of IL-7
signal transduction and the impact upon gene expression in T-cells. The fact that the JNK/JunD
pathway can have positive outcomes in IL-7 dependent T-cells highlights the need for continued
research in this area. The bioinformatics approach presented could provide a means to identify
potential gene expression changes that result from activation of JunD/AP-1 complexes in the
context of IL-7 signaling that can be tested for validation in different animal models of
immunological responses.
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CHAPTER 3: THE MAJOR ISOFORMS OF BIM CONTRIBUTE TO
DISTINCT BIOLOGICAL ACTIVITIES THAT GOVERN THE
PROCESSES OF AUTOPHAGY AND APOPTOSIS IN INTERLEUKIN-7
DEPENDENT LYMPHOCYTES
Introduction

Cell death is an essential process needed for tissue homeostasis. Central to the
modulation of apoptotic death are members of the B-cell lymphoma-2 (Bcl-2) family, which
includes pro-survival proteins, such as Bcl-2 and Bcl-xL, pro-apoptotic members, like the multidomain proteins, Bax and Bak, and a number of BH3-only proteins, such as Bad, Bid, Bim or
Bmf [42]. Of the BH3-only proteins, Bim emerges as an important regulator of T-lymphocyte
(T-cell) apoptosis. Bim is necessary for the death of autoreactive T-cells and is upregulated in Tcells upon death induced by T-cell receptor re-stimulation or growth factor withdrawal [39, 55].
Therefore, the key to understanding Bim’s role in the apoptotic program is appreciating its
relationship to T-cells.
In order to receive stimulatory and growth signals, T-cells need to migrate to
environments where these signals are found [153]. An example of one essential signal is the
cytokine, interleukin-7 (IL-7). IL-7 is mainly found in generative lymphoid organs as well as
some nonlymphoid tissues [19] and is produced in large part by accessory cells [115, 154]. The
heterodimeric IL-7 receptor (IL-7R), composed of both IL-7Rα and γc chains, is expressed by Tcells [155]. IL-7 is necessary for T-cell development, since disruption of either IL-7 or its
receptor resulted in defects in mice [12, 156] similar to the SCID (Severe Combined
Immunodeficiency Syndrome) phenotype in humans [157]. Evidence of the importance of IL-7
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is the fact that excess IL-7 underlies lymphoproliferation and lymphoma formation [158, 159],
indicating a role in the maintenance of peripheral T-cell homeostasis [15]. IL-7 supports T-cell
survival by maintaining a balance between the anti-apoptotic and pro-apoptotic Bcl-2 family
members [29, 160]. Indicative of a function in T-cell biology, loss of Bim could partially rescue
the immunodeficient phenotype of IL-7R-/- mice [44].
How the activity of Bim is regulated remains the focus of study. In some healthy cells,
Bim is sequestered by LC8, the light chain element of the microtubule-associated dynein motor
complex [77, 161], or is bound to anti-apoptotic proteins such as Bcl-2 or Bcl-xL at the
mitochondrial interface as was shown in T-cells [51]. Other regulatory mechanisms include
transcriptional regulation by FHKR (forkhead) through Foxo3a [56, 162], the gastric tumor
suppressor, RUNX [53] the post-translational phosphorylation of Bim at multiple sites [54, 68,
72, 78, 163-165]. We recently showed that IL-7 mediates the phosphorylation of BimEL,
contributing to its pro-apoptotic activity [52]. While a role for Bim as a pro-apoptotic protein is
well-recognized, Bim may also have unknown functions that go beyond its described deathpromoting activity. Bim exists as multiple isoforms generated through alternative splicing, with
the three major isoforms, BimEL, BimL, and BimS, part of a larger cohort of spliced forms [47,
62]. Some isoforms lack the BH3 domain or the dynein light-chain binding site, while others
lack phosphorylation sites [166], which result in the possibility that isoforms may have different
functions.
When extracellular nutrient sources are limiting, autophagy can support T-cell activation
through intracellular scavenging [167], but, under less well-understood conditions, autophagy
can also induce T-cell death, for example that of CD4 T-cells [168]. The individual contribution
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of the major isoforms of Bim to the processes of autophagy or apoptosis in T-cells is
unknown. To study this, we used Bim-containing and Bim-deficient T-cells, responsive to IL-7,
to examine the activity of the major isoforms in response to the cytokine. A novel role in
lysosome positioning was found for BimL that was dependent upon IL-7 and supported the
degradative phase of autophagy. In contrast, BimEL and BimS promoted IL-7 withdrawalinduced apoptosis.

These results demonstrated that Bim isoforms can participate in distinct

apoptotic and lysosomal/degradative activities in T-cells. While Bim has long been recognized
as an inducer of apoptosis, its role in supporting lysosome acidification suggests that controlled
manipulation of Bim isoforms could lead to novel applications in diseases like cancer.
Materials and Methods
Mice, Cell Lines and Culture Reagents
C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, Maine) and housed
at the University of Central Florida, Orlando, FL. Bim knockout (BimKO) mice (C57BL/6
background) [52], Rag-/- and IL-7-/-/Rag-/- mice were housed at NCI-Fredrick as previously
described [52]. This study was carried out in accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol
was approved by the Institutional Animal Care and Use Committee at the University of Central
Florida and NCI-Frederick. All efforts were made to minimize suffering.
The IL-7 dependent T-cell line, D1, was established from one clone that arose from Tcells isolated from a p53-/- mouse and immortalized as previously described [28]. Since its
establishment in 1997, the D1 cell line has been extensively used to study regulatory pathways
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controlled by IL-7 in T-cells [22, 29, 30, 82, 89] and was used to reveal the role of IL-7 in the
phosphorylation of BimEL [52]. To uncover the functional consequences of Bim deficiency and
evaluate the function of each Bim isoform, we needed a T-cell line that was IL-7 dependent and
also Bim deficient. To this end, we generated the SMoR T-cell line. Briefly, lympn node T-cells
were isolated from BimKO mice (see above). Cells were resuspended in RPMI 1640, 10% fetal
bovine serum (FBS), 5% Penicillin/Streptomyocin (Fisher), 0.1% B-mercaptoethanol
(Invitrogen) (complete medium), and 200 ng/mL IL-7 at a concentration of 5 x 105 cells/ml.
Using twenty 96-well, round bottom plates, 100 µl or approximately 104 cells/well were plated.
In total, almost 2 x107 cells were used for mutagenesis as follows. Ethyl-N-nitrosurea (0.64 mM,
ENU) in phosphate/citrate buffer was added to the cultures at 0, 7, 14, 21, and 28 days from
initial isolation. Mutagenized T-cells were grown with complete media and IL-7. After 3
months, one BimKO T-cell clone emerged that was immortalized and IL-7-dependent. This
outcome recapitulated the same observed when the original D1 cells line was cloned, in that a
single line emerged from the selection process for IL-7 dependency [28]. This experience
showed that generating immortalized IL-7 dependent T-cells is not possible unless underlying
mutations, such as Bim or p53 deficiency, are present. D1 and SMoR T-cell lines, both derived
from mice with a C56BL/6 background, were grown in complete medium and 50-200 ng/mL IL7. Early passages of D1 and SMoR cell lines were frozen as stocks and cells were used at less
than 10 passages from stocks.
Primary lymph node and splenic T-cells were isolated from both wild-type (WT) and
BimKO C57BL/6 mice as previously described [132].

Phoenix cells (see below) were

maintained in DMEM medium that was supplemented with 10% FBS.
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Reagents used as described in Figure Legends include pifithrin-α (p53 inhibitor) (SigmaAldrich), 3-Methyladenine (3-MA) (Class III phosphatidylinositol 3-kinase (PI3K) inhibitor)
(Sigma-Aldrich), Cathepsin III Inhibitor (pan cathepsin inhibitor, EMD), Pepstatin A (cathepsin
D inhibitor, EMD), Ca074 (Cathepsin B inhibitor, EMD), and Chloroquine (CQ) diphosphate
salt (Sigma-Aldrich).
Viability and Proliferation Assays

To quantitate cells undergoing apoptosis, the FITC Annexin-V Apoptosis Detection Kit
(BD Pharmingen) was used following manufacturer’s protocol. This kit utilizes a FITCconjugated Annexin-V antibody that recognizes phosphatidyl serine exposed on cells undergoing
early apoptosis, and contains PI (propidium iodide) which can permeate necrotic, membranedamaged cells. The Annexin-V/PI kit could not be used with cells expressing GFP (see below)
as the kit contains a FITC-conjugated antibody whose emissions would overlap the emission of
GFP-containing cells. To address this, the SYTOX® AADvanced™ dead cell stain solution and
the Violet Ratiometric Membrane Asymmetry Probe/Dead Cell Apoptosis Kit (Invitrogen) was
used following the manufacturer’s protocol. Apoptosis was indicated by membrane asymmetry
using the violet ratiometric dye, and membrane permeability was measured by Sytox uptake.
Sytox was visualized at 488nm and emissions collected at 695nm. The violet ratiometric probe
was visualized at 405nm and emissions collected at 450nm and 510nm. Cells were analyzed by
flow cytometry using the BD FACSCanto II flow cytometer. Analysis was completed using
FCSExpress (DeNovo) software. Viability was also assessed by determining morphological
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changes, cell shrinkage and granularity, using forward scatter (FSC) and side scatter (SSC)
gating by flow cytometry with an Accuri C6 flow cytometer.
Proliferation was measured by labeling cells with CFSE as previously described [88, 132,
169]. For CFSE labeling, one million cells were treated with 2 µM CFSE (Molecular Probes)
staining solution (PBS + 0.1% BSA) for 10 minutes and then washed to remove excess label.
The division of cells was determined by measuring CFSE fluorescence by flow cytometry after
72 hours of culture with or without IL-7.

The generation number for the population was

determined from a best fit of these data using the Proliferation module for the FCS Express
software (DeNovo). Unstimulated CFSE-containing cells were used to determine the peak
corresponding to the undivided population.
Bim inhibition by small interfering RNAs
One-to-two million D1 cells were treated with 1-2 nM BCL2L11 SMART pool siRNA
(Dharmacon) and Accell delivery media (Dharmacon) supplemented with 1% FBS, and IL-7 (50
ng/ml) for 24 hrs. After 24 hours, cells were deprived of IL-7 and re-plated in media containing
the siRNA alone, for 48 hours. SMART pool siRNA contains four sequence variations of
siRNAs to eliminate non-specific interactions. Non-targeting siRNA (NT siRNA) containing a
FAM reporter sequence was used as a delivery control, and was comparable to treatment with
Accell media alone. Cells were analyzed using flow cytometry and confocal microscopy.
Quantitative PCR
Ten million D1 cells, per experimental condition, were cultured with or without IL-7 as
described above, were re-suspended in 1 ml of TRIzol reagent (Invitrogen). Total RNA was
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extracted from the cells using the reagent according to the manufacturer’s instructions. Each
cDNA template was synthesized from total RNA by reverse transcription with iScript cDNA
Synthesis kit according to manufacturer’s instructions. Quantitative analysis of cDNA
amplification was assessed by incorporation of SYBR Green (ABI 4385370) into doublestranded DNA. For mouse Bim: forward 5’- CGACAGTCTCAGGAGG AACC-3’, reverse 5’CCTTCTCCATACCAGA

CGGA-3’.

For

β-Actin,

forward

primer

5’-GAAA

TCGTGCGTGACATCAAAG-3’ and 5’-TGTAG TTTCATGGATGCCACAG-3’ reverse primer
were used. Reactions contained Fast SYBR Green Master mix (1X), β-Actin primers at 50 nM
or Bim primers at 100 nM, and 3-4 µg cDNA template. Thermal cycling conditions were as
follows: 40 cycles of 30 sec at 95 °C followed by 45 sec at 57 °C, and 60 sec at 72 °C,
denaturing, annealing and extension temperatures, respectively. All cDNA samples were
processed using the ABI Fast 7500 and analyzed using ABI Sequence Detection Software
Version 1.4. The difference in mRNA expression was calculated as follows: fold change = 2ΔΔCt, ΔΔCt is equal to the change in ΔCt values over time after normalization to β-actin. ΔCt is
equal to the difference between the endogenous control Ct and target gene Ct values.
Immunoprecipitation and Immunodetection
For preparation of whole cell lysates, 37-45 million cells were lysed using the Cell Lysis
buffer (Cell Signaling) in the presence of protease inhibitors (Roche). In the case of primary
cells, 1 to 3 million cells per condition, were used. For immunoprecipitation, cell lysates were
pre-cleared with Protein A/G Sepharose beads (Santa Cruz), incubated with anti-dynein antibody
and immunoblotted for Lamp1 and Rab5 as described below. For immunoblotting, subcellular
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fractions (from gradients, see below), whole cell lysate samples, or co-immunoprecipitated
samples were run in 10% or 12-15% SDS-PAGE gels, and proteins transferred to nitrocellulose
membranes by semi-dry transfer (BioRad) or wet transfer (Novex) following manufacturers’
protocols.

Membranes were washed and probed with primary antibodies (see below) and

incubated with horseradish peroxidase (HRP)-conjugated (Santa Cruz) or fluorescenceconjugated secondary antibodies (LICOR). Signal was detected using either chemiluminescent
fempto substrate (SuperSignal West Fempto; ThermoSci) or the LICOR Odyssey detection
system. The primary antibodies used in this study were as follows: a rabbit polyclonal antibody
against amino acids 22 to 40 of human Bim protein (anti-Bim; Calbiochem), Bim (rat
monoclonal 14A8; Calbiochem), Lamp1 (mouse monoclonal 1D4B; developed by J. Thomas
August, Developmental Studies Hybridoma Bank, University of Iowa), Prohibitin (rabbit
polyclonal ab28172; Abcam), p38 (Santa Cruz), Bcl-2 (Santa Cruz), Rab5, an early endosome
marker (Abcam), Cathepsin B (Abcam), Dynein (Abcam), p62 (Cell Signaling), and LC3B
(Abcam). Quantitation of the bands was performed using ImageJ software, taking the average of
the three separate measurements for each band.
Cell surface protein analysis
Surface expression of IL-7R expressed on T-cells was assessed by flow cytometry using
a PE-conjugated anti-IL-7R antibody (BD Biosciences) as previously described [88, 132, 169].
A PE-conjugated isotype matched antibody was used as a control for non-specific staining.
One–two million D1 or SMoR cells were incubated with or without IL-7 for 18 hours and then
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treated with saturating amounts of the appropriate antibody for 20 minutes, washed in buffer
(PBS + 0.1% BSA) and analyzed by flow cytometry on the Accuri C6 flow cytometer.
Measurement of intracellular pH
Cells (D1, SMoR, primary C57BL/6 and BimKO) were resuspended in Hanks
supplemented with 25mM HEPES (Invitrogen), 1% FBS, and 1µM BCECF-AM (Molecular
Probes). Intracellular pH-dependent changes in fluorescence were measured by flow cytometry,
using methods previously described [170, 171]. To establish a pH calibration curve, cells were
re-suspended in high-potassium HEPES buffer (25 mM HEPES, 145 mM KCl, 0.8 mM MgCl2,
5.5 mM glucose, and DDH2O) at pH standards (5.9, 6.5, 7.0, 7.2, and 7.8) and nigericin (10 µM)
added followed by BCECF-AM. Measurements were acquired using a BD FACSCanto II
cytometer excited with a 488 nm laser, with emissions were filtered through 525 nm and 610
nm. Dead cells were excluded by forward- and side-scatter gating. pH values were determined
by measuring the absorbance ratio between 525 nm (green fluorescence) and 610 nm (red
fluorescence), the latter of which compensates for dye concentration, volume, and cell size.
Live Cell Imaging/ Microscopy
For imaging, cells were plated in 24-well glass bottom dishes (MatTek) that had been
washed with 1N HCl and PBS. Cells were supplemented with 1 µM LysoSensor immediately
before imaging.

LysoSensor probe is cell membrane permeant and exhibits pH-dependent

increases in fluorescence intensity upon acidification. For imaging of retrovirus-infected cells,
dishes were coated with 8 µg/mL Retronectin (Takara), followed by the retroviral supernatant,
prior to adding cells. At 20 hours post-infection, 1 µM LysoTracker (Molecular Probes) was
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added to cell culture in RPMI complete media immediately prior to imaging. LysoTracker
probes are also cell membrane permeant and contain a fluorophore bound to a weak base that
becomes partially protonated upon neutral pH exposure and selectively stains acidic organelles in
live cells, although fluorescence is independent of pH changes. Fluorescent images were
acquired with the UltraView spinning disc confocal system (PerkinElmer) with AxioObserver.Z1
(Carl Zeiss) stand, and a Plan-Apochromat 40x/1.4 Oil DIC objective. Z-stacks and extended
focus of scanned images were created and modified using the Volocity 5.5 image processing
program (PerkinElmer). LysoSensor-treated samples were excited at 405 nm.

To detect

Lysosensor fluorescence, emissions between 445 nm and 615 nm were collected for more neutral
pH vesicles (assigned an arbitrary yellow color), and between 525 nm and 640 nm for acidic
vesicles (assigned an arbitrary blue color). LysoTracker stained samples were excited at 561 nm
and emissions collected between 525 nm and 640 nm. Transmitted light images were collected
for DIC. For SMoR cells transfected with pMIG, BimEL, or BimL plasmids, total fluorescence
and the number of GFP positive events, with the removal of auto fluorescent outliers, per field,
were obtained using Volocity 5.5. GFP was acquired using a 488 nm laser, and emissions were
collected at 525 nm and 640 nm.
Retroviral Transfection
The bi-cistronic plasmids, pMIG, pEco, BimEL-pMIG, BimS-pMIG, and BimL-pMIG
were made as previously described [52]. The retroviral infection technique was optimized
specifically for the D1 and SMoR cell lines [52]. A Phoenix-Eco packaging cell line (Orbigen)
was transfected with bi-cistronic plasmids containing a Bim isoform (or none, termed pMIG) and
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GFP. Cells were transfected using TransIT-LT1 reagent (Mirus). The supernatant containing the
retrovirus was harvested after 48 hours and loaded onto Retronectin (Takara)-coated plates. One
million cells per mL were incubated in supplemented media containing Polybrene (Santa Cruz, 8
µg/mL), either in the presence or absence of IL-7, and added to the plates for several hours.
Adoptive transfer of T-cells and Chloroquine in vivo treatment
C57BL/6 and BimKO LN cells were isolated and suspended in PBS containing 5% FBS.
Cells were incubated for 10 min with CFSE (Invitrogen) following previously established
methods [52]. Rag-/-/IL-7-/- double knockout or Rag-/- recipient mice were irradiated with 3 Gy
whole body γ-irradiation 4 hours prior to injection. Five million CFSE-labeled cells were then
suspended in PBS and adoptively transferred into the previously irradiated Rag-/-, and Rag-/-/IL-7/-

double knockout mice. Mice were intraperitoneal injected with 60 mg/kg chloroquine within

24 hours, and again, after 48 hours. Mice were euthanized within 72 hours, spleens and lymph
nodes recovered, and T-cells isolated and utilized for analysis as previously mentioned [88].
Recovered cells were analyzed for loss of CFSE label by flow cytometry (Accuri C6 flow
cytometer) and calculation of generation times performed using FSC Express (DeNovo)
proliferation module software.
Subcellular Fractionation
Cells were seeded to 80-90% confluence. For lysosome preparations: 200 mg (140
million) cells were harvested by isotonic lysis buffer according to protocol from the Lysosome
enrichment kit (Pierce) and prepared for density gradient ultracentrifugation. Enriched lysosomal
fractions were layered onto an iodixanol gradient (17%, 23%, 25%, 27%, 29%, and 30%
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Optiprep) and subjected to ultracentrifugation using an Optima L-100XP Ultracentrifuge.
Gradients were fractioned in 500 µL aliquots (Fractions 1-10) using an Auto Densi-Flow
(Labconco). Enriched preps were utilized for downstream processing or re-suspended in sample
buffer for gel-electrophoresis (see above).
Statistics
Statistical analysis and significance was determined using Prism 5 (Graphpad) for
Windows, Version 5.02. P values determined are shown in Figure Legends.
Results
Bim has multiple functions, promoting death as well as growth in IL-7 responsive cells
It is generally accepted that Bim inhibits the survival activity of anti-apoptotic members
of the Bcl-2 family [172], and that it has an important, although poorly understood, role in T-cell
biology [44]. Our previous studies showed that in T-cells, IL-7 regulated the activity of BimEL
through phosphorylation [52], but the activity of other major isoforms, BimL and BimS, relative
to IL-7 signaling remained unknown. Using primary LN T-cells from C57BL/6 or BimKO mice,
we evaluated the effect of in vitro culture with IL-7, using methods we previously established
[88, 132]. Shown in Figure 11A are representative results indicating in the absence of IL-7 that
the loss of Bim provided short-term protection (3 days) from death, although such LN cells
eventually died in in vitro culture. Viability of cells was determined by assessing cell shrinkage
and increased granularity detected by forward scatter (FSC) and side scatter (SSC) gating using
flow cytometry. Because primary T-cells do not uniformly respond to an IL-7 signal (i.e. CD8
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T-cells proliferative at the expense of CD4 T-cells) [88, 132] and may need additional signals
through the T-cell receptor (TCR) for optimal growth [87], we used an IL-7-dependent T-cell
line, D1, to examine the activity of Bim in response to IL-7. The generation of the D1 cell line
has been previously described [28] and a number of studies have demonstrated its biological
relevance in the context of IL-7 signaling [22, 29, 30, 82, 89, 92]. Upon IL-7 withdrawal, cell
death, as indicated by increased Annexin-V/PI staining, was detected in D1 cells within 36
hours, and death was maximal by 48 hours (Fig. 11B) [28]. To determine whether loss of Bim
could protect D1 cells from IL-7 deprivation, cells were treated with Bim siRNA, to inhibit total
Bim. We observed a 40% reduction in Bim mRNA levels in cells treated with Bim siRNA as
compared to cells treated with control siRNA (Fig. 11C). Note that the siRNA methodology
limits cell numbers to a few million, which is below the threshold for detection of endogenous
Bim protein. The siRNA-induced decrease in Bim expression led to reduced apoptosis in D1
cells deprived of IL-7 as indicated by the increased percentage of viable cells (Annexin-V/PI
negative) detected (Fig. 11C). For this experiment, D1 cells were incubated with siRNAs for 72
hours, of which the first 24 hours were in presence of IL-7 and the last 48 hours were in the
absence of IL-7. To determine whether IL-7 regulated the gene expression of Bim, we examined
the levels of total Bim mRNA in D1 cells cultured with or without IL-7. Using quantitative
PCR, we observed that Bim mRNA levels increased in the absence of IL-7 – specifically after
15-18 hours of cytokine withdrawal, indicating that the gene expression of Bim, was in part, IL-7
responsive (Fig. 11D). These results supported the conclusion that Bim was among the effectors
of death in response to IL-7 deprivation.
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To evaluate the biological consequence of Bim deficiency in IL-7-dependent T-cells and
study the function of each major isoform without the limitations imposed by either primary
lymphocyte cultures or siRNA treatments, we needed a Bim-deficient and IL-7-dependent T-cell
line. To this end, we generated the SMoR T-cell line from BimKO mice as described in
Materials and Methods. To demonstrate that the expression of Bcl-2 family members in D1 or
SMoR cells was not altered by either the immortalization process or loss of p53 or Bim, we
examined Bcl-2 and Bax, proteins whose expression or activity, respectively, is regulated by IL7 [28, 29, 131]. As shown in Figure 12A, we found that the two cell lines displayed minimal
differences in the total levels of Bcl-2 or Bax detected in response to IL-7.

Bcl-2 levels

decreased in the absence of IL-7 and Bax distributed between the cytosol and mitochondria (Fig.
12A). Next, we determined whether, lacking functional Bim, SMoR cells underwent death upon
IL-7 withdrawal.

Apoptosis was detected using Annexin-V/PI staining, and viability was

determined by assessing changes in cell size and granularity. Shown in Figures 12B and 12C,
we observed decreased numbers of Annexin-V/PI positive SMoR cells after 36 hours of IL-7
deprivation and sustained viability (50-60%) through 48 hours of IL-7 loss. These results
indicated that IL-7-dependent, Bim-deficient SMoR cells are useful for the study of Bim function
in IL-7 dependent T-cells and confirmed that Bim was contributing to death induced by IL-7
loss.
As shown and previously reported, D1 cells underwent death between 24-48 hours after
IL-7 withdrawal (Fig. 12C) [28].

Stimuli that induce apoptosis can also trigger DNA damage

and p53 is usually responsive to this mechanism [173]. To show that protection from IL-7withdrawal-induced death in SMoR cells was likely due to loss of Bim and not the presence of a
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possible p53-mediated activity, we treated cells with pifithrin-α, originally described as a p53
inhibitior [174], but also shown to protect from DNA-damaged induced apoptosis [175]. No
differences in viability of SMoR cells or D1 cells, cultured with IL-7, were detected upon
pifithrin treatment (Supplemental Figure 1). Withdrawal of IL-7 and the addition of pifithrin
increased the death observed in D1 cells, suggesting that both p53–dependent and p53independent death mechanisms were involved. In contrast, SMoR cells were resistant to death
induced by increasing doses of pifithrin-α (Supplemental Figure 1), indicating that the loss of
Bim was likely a key factor that contributed to protective effect observed upon IL-7 withdrawal
(Fig. 12C). Note that upon extended IL-7 deprivation, SMoR cells eventually died after 4 days
(data not shown). Hence, the loss of Bim did not prevent but delayed the death of cells deprived
of IL-7.
Other parameters of importance are cytokine-driven proliferation and viability under
conditions of nutrient deprivation. To measure the growth of D1 and SMoR cells in response to
IL-7, we used the dye, CFSE. CFSE divides with each cell replication cycle and can be used to
measure generation times as shown in Figure 12D. D1 cells rapidly divided in response to IL-7,
replicating 1-2 times per day over the three days of evaluation, while SMoR cells divided 1-2
times over the same three day period (Fig. 12D). Therefore, loss of Bim, while providing
protection from IL-7-induced cell death (Fig. 12C), decreased cell replication rate. The surface
expression of the IL-7R was measured to determine whether the slow growth of SMoR cells was
due to decreased IL-7R levels. This was not observed, as is shown in Figure 12E. Both D1 and
SMoR cells displayed comparable levels of IL-7R that increased upon cytokine withdrawal, a
pattern that is typical of what others have reported [11]. In fact, compared to D1 cells, SMoR
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cells had slightly higher amounts of surface IL-7R relative to maximal receptor levels achieved
in the absence of IL-7 (Fig. 12E). SMoR cells, but not D1 cells, were also more sensitive to
glucose deprivation and decreased viability when cultured under conditions of minimal glucose
(4 mM) (Fig. 12F). These results suggested that loss of Bim conferred partial protection from
cell death caused by growth factor removal but also caused a growth disadvantage that resulted
in reduced replication and sensitivity to nutrient loss that was not dependent on the levels of IL7R.
Bim supports intracellular acidification and formation of acidic vesicles
In order to investigate the activity of Bim in IL-7 dependent T-cells that could account
for the observed biological effects, changes in intracellular pH were examined. Cytosolic
acidification can be a hallmark of apoptosis and has been linked with lysosomal proton release
upon lysosomal permeabilization [176, 177]. Changes in pH can also correlate with proliferative
status [178]. A time course experiment, measuring intracellular pH, showed that D1 cells acidify
after 24-30 hrs of IL-7 withdrawal, consistent with morphological changes indicative of cell
death (Fig. 13A).

In SMoR cells, IL-7 deprivation did not induce acidification and cells

remained more alkaline over the entire course of evaluation (Fig. 13A). These results were
confirmed using LN T-cells from WT and BimKO mice (Fig. 13B). While we previously
showed that D1 cells transiently alkalinize 6-8 hours after IL-7 withdrawal due to the activity of
the sodium hydrogen exchanger 1 (NHE1) [29], this is an active mechanism induced by
apoptotic stimulus [171].

In contrast, the increased intracellular pH of SMoR cells was

detectable in the presence of IL-7 and did not change even during IL-7 withdrawal.
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These data suggested that Bim loss was affecting a biological activity that impacted upon
intracellular pH. One possibility could be that the loss of Bim disrupted normal lysosomal
functioning.

To determine whether the morphology of lysosomes was different in Bim-

containing and Bim-deficient cells, endosomes and lysosomes were visualized using LysoSensor
probe. LysoSensor measures the pH of acidic organelles and distinguishes more neutral vesicles
of higher pH (i.e. endosomes) from acidic or lower pH vesicles (i.e. late endosomes/lysosomes).
In parallel studies, the probe LysoTracker was used to visualize lysosomal content and show that
no pH-dependent changes in the probe occurred in the organelles imaged, demonstrating that
Lysotracker and LysoSensor staining were comparable (Supplemental Figure 2).

Live cell

imaging was performed to view results from lysosome probes. In Figure 13C, using LysoSensor,
we observed a difference in the distribution and aggregation of less acidic (arbitrarily assigned a
yellow color) compared to more acidic vesicles (arbitrarily assigned a blue color) in D1 cells
grown with or without IL-7. The dispersed distribution of acidic vesicles within cells cultured
with IL-7 became clumped and aggregated as IL-7 was deprived, indicating a potential increase
in endosome/lysosome fusion. This is best observed in the 3-dimensional (3D) single-cell
enlargement showing intense staining of merged fluorescent signals (appearing white in areas)
from acidic vesicles (Fig 13C). When D1 cells were treated with Bim siRNA, a distinct change
was observed in that aggregation was decreased (no intense staining of merged fluorescence or
white areas) and increased detection of less acidic vesicles (Fig. 13D). This is most clearly seen
in the merged 3D enlargement. These results suggested that loss of Bim had a negative effect
upon the distribution of acidic vesicles (Fig. 13E) in the presence or absence of IL-7. In total,
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increased intracellular alkalinity and decreased acidic vesicles in Bim deficient cells suggested
that Bim could have a function in the maintenance of lysosomal activity.
The absence of Bim leads to impairment of the later degradative phase of autophagy
Our data showing that SMoR cells lacking Bim were less viable under conditions of
limiting glucose (Fig. 12F) and has less acidic vesicles (Fig. 13E), suggested that Bim could be
involved in a novel biological activity, that of self-eating or autophagy. Autophagic digestion
can contribute to the recycling of cytoplasmic components and promote survival, inhibition of
which accelerates apoptosis [179]. Alternatively, autophagy can directly lead to cell death [180].
To examine this, we used the class II PI3K inhibitor, 3-MA, which can inhibit autophagy under
conditions of nutrient or cytokine deprivation [181].

We observed that 3-MA treatment

accelerated cell death in the absence of IL-7 - from 32% (untreated) to 49% (3-MA)
apoptotic/necrotic cells (Fig. 14). Treatment with 3-MA had only a minor impact in Bim
deficient SMoR cells and did not greatly increase the percent of apoptotic/necrotic cells – from
8% (untreated) to 12% (3-MA) (Fig. 14). We also observed that treatment with 3-MA caused
some death in the presence of IL-7 (Fig. 14), which could be due to the effect of this inhibitor on
PI3 Kinases [181].
To assess autophagic activity, the levels of LC3-I and LC3-II were measured. LC3-I is
cytosolic, while LC3-II, which is conjugated with phosphatidylethanolamine (PE), is associated
with autophagosomes and less so with autolysosomes [182, 183]. Normally the amount of LC3II correlates with the number of autophagosomes and is degraded as a result of autophagy. As
shown in the representative experiment in Figure 15A, LC3-I and LC3-II levels varied slightly in
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D1 cells cultured with IL-7 for 6 or 18 hours, with more LC3-I and less LC3-II detected at 18
hours. In contrast, D1 cells deprived of IL-7 for 6 hours (or at 18 hrs) had an increased ratio of
LC3-II to LC3-I, suggesting an increased number of autophagosomes (Fig. 15A).

In

comparison, SMoR cells displayed higher amounts of both LC3-I and LC3-II, suggesting that
either autophagosomes were increased in these cells or that degradation of LC3 was reduced,
allowing the protein to accumulate (Fig. 15A). Note that by 18 hours of IL-7 deprivation, levels
of LC3-I and II were negligible in both D1 and SMoR cells. Next, we examined the degradation
of p62 (a.k.a. SQSTM1) as an indicator of autophagic flux.

The targeting of p62 to the

autophagosome formation site does not require LC3, however, once there, p62 binds to LC3 and
is entrapped in autophagosomes where, upon fusion with lysosomes, it is degraded [184].
Hence, impairment of the degradative phase of autophagy can result in the accumulation of p62.
We observed that in D1 cells, the levels of p62 declined when IL-7 was withdrawn, suggestive of
increased autophagic degradation (Fig. 15A). This did not occur in SMoR cells where p62 levels
remained elevated (Fig. 15A). We confirmed these results using freshly isolated LN T-cells
from BimKO and WT mice. In comparison to WT cell, we detected elevated levels of LC3-II
compared to LC3-I in BimKO cells, with a greatly increased ratio of LC3-II to LC3-I and
increased accumulation of p62 (Fig. 15B). This data suggested that loss of Bim did not impair
autophagosome formation, since LC3-II and p62 were detected, but could suggest a problem
with the degradative phase of autophagy that allowed these proteins to accumulate.
To study lysosomal-mediated degradative activity, we used the inhibitor, chloroquine
(CQ), to inhibit lysosomal acidification. As a comparison, we also used 3-MA. Within the
timeframe of the experiment with freshly isolated LN cells, these inhibitors did not greatly

63

impact upon LC3 and p62 protein levels (Fig. 15B).

However, inhibition of lysosomal

acidification with CQ did increase LC3-II accumulation in D1 cells grown with or without IL-7
(Fig. 15C) and also increased the amount of p62 (Fig. 15D), indicating that these proteins were
being degraded as a result of lysosomal activity. Treatment with 3MA had a similar, though
slightly lesser, effect (Figs. 15C-D).

This suggested that in Bim-containing D1 cells,

autophagosome formation was occurring, followed by autolysosomal-mediated protein
degradation.

In SMoR cells CQ treatment also caused some accumulation of LC3-II but to a

lesser extent than in D1 cells (Fig. 15C). As example, in D1 cells cultured with IL-7, CQ
treatment caused an almost three-fold increase in LC3-II as compared to SMoR cells in which a
slightly more than two-fold increase was observed (Fig. 15C). Note also that in SMoR cells,
higher levels of LC3-I were found that resulted in lower ratios of LC3-II to LC3-I. The amount
of p62 protein was also elevated in SMoR cells and was not significantly increased by CQ or
3MA treatments (Fig. 15D). These results supported the idea that Bim is needed to enable the
degradative phase of autophagy, impairment of which could have a negative feedback upon the
initiation of autophagy and LC3 conversion levels.
To strengthen the conclusion that the lysosomal/degradative phase of autophagy is
defective in Bim-deficient cells, SMoR cells were treated with inhibitors of cathepsin activity or
lysosomal acidification. The expectation was that Bim deficiency would render SMoR cells
resistant to the effect of these inhibitors. In Figure 16A, a representative experiment with SMoR
cells is shown in which treatments with a pan-cathepsin inhibitor (CI) had little effect on IL-7withdrawal induced apoptosis. Results were confirmed with specific inhibitors of aspartic
proteases, like cathepsin D (pepstatin A) and cathepsin B (Ca074) (Fig. 16B).
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With the

autophagy process intact, D1 cells showed the anticipated effect of accelerated cell death upon
CI (Fig. 15A) and pepstatin A (Fig. 15B) treatments. Note that inhibitors of specific cathepsins
were less effective than the pan-cathepsin inhibitor (CI) likely because the specific cathepsins
inhibited were less active in these cells.

To further examine the effect of Bim upon the

lysosomal activity, CQ was used [185]. CQ is being tested as a therapeutic agent and is welltolerated at treatment doses [186]. A CQ dose response curve was experimentally determined
(data not shown). The representative experiment in Figure 16C revealed in the presence of IL-7,
CQ caused less death in SMoR cells, and, upon IL-7 withdrawal, SMoR cells were resistant to
the effects of CQ and did not accumulate large numbers of late-apoptotic/necrotic cells. As
expected, Bim-containing, D1 cells underwent accelerated IL-7-induced apoptosis upon CQ
treatment, with increased amounts of apoptotic/necrotic cells detected, as measured by AnnexinV/PI staining (Fig. 16C). These results suggested that the autophagy defect in Bim-deficient
cells might be associated with the formation of degradative autolysosomes. Findings in Figure
13, that SMoR cells were more alkaline and accumulated fewer acidic vesicles provide additional
support for this idea.
Studies performed with T-cell lines were extended to mice to determine whether
inhibition of lysosome acidification accelerated the death of WT, but not BimKO, T-cells
adoptively transferred to Rag-/-IL-7-/- mice. Recipient Rag-/- (control) or Rag-/-IL-7-/- mice were
treated with CQ as described in Methods, and splenic CFSE-labeled T-cells were recovered for
analysis. Generation or doubling time was determined by the number of cycles in which the
CFSE label was halved during each cell division. Results are shown in Figures 16D-E. We
observed that WT T-cells transferred to control Rag-/- mice proliferated equally well in the
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absence or presence of CQ (Fig. 16D). The same was true with BimKO T-cells, although the
total cell number was slightly reduced during CQ treatment (Fig. 16E). When WT cells were
transferred to Rag-/-IL-7-/- mice, proliferation was greatly reduced and a significant number of
cells remained undivided (Fig. 16D). Moreover, loss of Bim did not rescue T-cell expansion in
the absence of IL-7 (Fig. 16E). However, CQ treatment did complement Bim deficiency and
restored T-cell growth in mice lacking IL-7 (Fig. 16E). Note that we observed a similar finding
in that SMoR cells were more resistant to CQ treatment (Fig. 16C). CQ treated WT T-cells
transferred to Rag-/-IL-7-/- mice did not proliferate and fewer cells were recovered than was
observed for untreated WT cells under IL-7-deficient conditions (Fig. 16D). These results
confirmed the in vitro results described for T-cell lines (Fig. 16C) that inhibition of lysosomal
activity can accelerate death during an apoptotic stimulus, like IL-7 withdrawal, and that this
does not occur in cells lacking Bim.
Bim isoforms differentially contribute to apoptotic and lysosomal activities
Results obtained indicated that Bim could have possible roles supporting both apoptosis
and the degradative, lysosomal-mediated phase of autophagy. The question remained – how can
Bim function in both capacities? A possible answer could be that Bim isoforms have different
functions in these processes. To determine this, we examined the expression of the major
isoforms of Bim in response to IL-7. To localize the major Bim isoforms, BimEL, BimL and
BimS, to organelles, density gradient separation of cell lysates was performed. This procedure
allows the separation of organelles and membrane-encased vesicles based upon lipid and protein
content. In Figure 17A, a representative experiment shows that in Bim-containing D1 cells,
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cultured with IL-7, we detected BimL protein in fraction 3 that is associated with late
endosomes/lysosomes and marked by the highest concentration of Lamp1 (fractions 1-4). Note
that Lamp1 is diagnostic for lysosomal-associated disorders [187] and thus a marker for
lysosome content. A small amount of the early endosome marker, Rab5, also associated with
same fraction. As a control, we observed that Bcl-2 associated with those fractions in which
Prohibitin, a mitochondrial marker, was found (fractions 3-5, but highest in fraction 4) as well as
small amounts of the other major Bim isoforms (Fig. 17A).
Performing gradient centrifugation using cell lysates from IL-7-deprived D1 cells, we
detected increased amounts of BimEL and BimS that associated with mitochondrial fractions
marked by Bcl-2 and Prohibitin (fractions 3-6, but mostly in fraction 4) and decreased amounts
of BimL that associated with lysosomes (Fig. 17A). Interestingly, more BimEL was seen across
fractions 1-5, while BimL and BimS were concentrated in the mitochondrial-associated fractions.
We also observed an increase in Lamp1 staining in the lightest density fraction (fraction 1) and a
weak but dispersed distribution of Rab5. These results demonstrated that the isoforms of Bim
could localize to different organelles based on the lipid/protein content in the presence of IL-7 as
compared to the absence of IL-7. Significantly, we found that BimL was associated with
lysosome fractions in the presence of IL-7.
In Figure 17B, similar density gradient experiments performed with SMoR cells are
shown. Overall Lamp1 levels were reduced in the lighter density fractions (fraction 3 in the
presence of IL-7 and fraction 1 in the absence of IL-7). While Lamp1 staining was decreased,
Rab5 staining was increased, which supported the imaging experiments in Figure 3 and
suggested that early endosomes (or more neutral vesicles) were more abundant in the absence of
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Bim. Like in D1 cells, Bcl-2 in SMoR cells was mainly associated with mitochondrial fractions
(Fig. 17B). Note that SMoR cells, like freshly isolated BimKO LN and spleen cells (see
Supplemental Figure 3), express polypeptides that migrate in a gel at the same levels of
endogenous BimL and BimS.
Results shown indicated that BimL may directly associate with lysosomes in IL-7
cultured cells.

This could occur through association with the microtubule motor, dynein.

Previous studies had shown an interaction between Bim and dynein that sequestered that BH3only protein in non-apoptotic cells [77, 188]. To determine whether Bim facilitated the binding
of lysosomes to dynein, we performed a co-immunoprecipitation experiment. Lysates were
prepared from D1 cells cultured with IL-7 and immunoprecipated with an anti-dynein antibody.
Blots were probed for Lamp-1 as indicator of lysosome cargo. As shown in Figure 17C, dynein
co-immunoprecipated with Lamp1 in D1 cells grown with IL-7.

We could not co-

immunoprecipate dynein with Lamp1 in SMoR cells grown with or without IL-7 or with D1 cells
deprived of IL-7 – basically cells lacking or with reduced content of BimL. As control, we
found that Rab5 associated with dynein independently of IL-7 or Bim (Fig. 17C). Additionally,
we observed that all the immunoprecipitated versions of Lamp1 and Rab5 ran slightly slower on
the gels indicating possible modifications that enable complex formation. Also, the stronger
detection of Lamp1 in the input lanes for SMoR cells as compared to other blots was due to
significantly increased amount of protein input used to maximize detection of coimmunoprecipitates.
Next, BimEL and BimL were expressed in SMoR cells using a retroviral method. This
method necessitated reduced numbers of cells as compared to blots in Figures 17A-C. Shown in
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the representative experiment in Figure 17D, we found that expression of BimL, but not BimEL,
was able to restore the interaction of dynein with Lamp1-containing vesicles in SMoR cells,
significantly increasing the detection of Lamp1 (and some Rab5) well above endogenous levels.
Thus, BimL could function as an adaptor for dynein to facilitate the loading and fusion of
lysosomes within cells.
The role of BimL as the mediator of lysosomal positioning through its interaction with
dynein, was examined by expressing the three isoforms of Bim in SMoR cells, and observing the
effects upon lysosomal distribution and cell viability. To perform these experiments we used the
probe, LysoTracker. Because we were imaging GFP positive cells to track those that were
expressing the isoforms of Bim, we could not use LysoSensor as in Figure 13 since the
fluorescent signals overlapped. We used the same live cell imaging technique as shown in
Figure 13. In addition, in each image set, a dot plot displays cell death measured by Sytox
uptake and membrane asymmetry. Images were collected at the final experimental time point.
Results in Figure 18A, demonstrated that SMoR cells expressing the empty vector, pMIG, had
dim LysoTracker staining, and viability upon retroviral expression was 62%. When BimEL was
expressed, we noticed lysosomal staining with little or no vesicle aggregation evident (Fig. 18B),
and viability decreased to 45%. In contrast, expression of BimL resulted in notable lysosomal
aggregation, likely indicative of fusion (Fig. 18C), with viability stable at about 49-50%. For
comparison, we also expressed BimS, which was the most toxic of the isoforms, causing rapid
cell death with most of the GFP positive cells in the field acquiring a shrunken, and apoptotic
morphology (Fig. 18D), and viability dropping to 30%.

69

Conclusions
In summary, our results revealed that the major isoforms of Bim has defined functions in
the cell maintenance and the apoptotic processes occurring in T-cells responsive to IL-7. In Tcells receiving an IL-7 signal, BimL plays an essential role in lysosomal positioning through
interactions with dynein that promote the formation of autolysosomes during the degradative
phase of autophagy.

BimEL associates with mitochondria in a pro-apoptotic manner, and

expression of BimS further promotes the cell death process. BimL, therefore, functions in the
presence of IL-7 to support lysosomal acidification, while BimEL and BimS are active during
IL-7 deprivation to cause T-cell apoptosis.
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Figure 11. Loss of Bim partially protects IL-7 dependent cells from apoptosis.
(A) Lymph node T-cells, isolated from WT C57BL/6 or BimKO mice and cultured with or without 150 ng/ml of IL7 for 3 days as described in Materials and Methods, were assessed for viability as determined by cell morphology,
assessing size (forward scatter (FSC)) and granularity (side scatter (SSC)) by flow cytometry. (B) Cytokine
withdrawal-induced death of D1 cells, grown with or without 50 ng/ml IL-7 (36 hours), was measured by surface
expression of phosphatidyl serine using FITC-conjugated Annexin-V antibody. Membrane permeability was
assessed by propidium iodide exclusion (PI), analyzed by flow cytometry. Dot plots show percentages representing
the population of cells that are non-apoptotic (lower left quadrant), early apoptotic (upper left) or late
apoptotic/necrotic (upper right). Quadrants were established using controls. (C) D1 cells were pre-treated with nontargeting control or BCL2L11 SMART pool siRNA (Dharmacon) for 24 hours with IL-7. Cells were then deprived
of IL-7 for 48 hours. Efficacy of Bim siRNA upon Bim mRNA levels (graph) was established by measuring total
Bim gene expression by quantitative PCR in which RQ value (or fold change in gene expression) = 2-ΔΔCt. IL-7withdrawal-induced death in D1 cells, treated with either non-targeting control (Control) or Bim siRNA, is shown
(dot plots) using Annexin-V/PI staining as described above. (D) Total Bim gene expression in D1 cells, in the
presence or absence of IL-7, was measured for the times indicated by quantitative PCR. RQ (Fold change) = 2-ΔΔCt.
Data shown in this figure are representative of a minimum of three independent experiments. * P < 0.05, **P <
0.0241, ***P < 0.0001.
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Figure 12. Characterization of SMoR cells.
(A) Bcl-2 and Bax expression in D1 and SMoR cells, cultured with or without IL-7 for 18 hours, was examined by
immunoblot. Prohibitin and p38 MAPK shown are loading controls for mitochondrial and cytosolic content,
respectively. (B) Cytokine-withdrawal-induced death of SMoR cells, grown with or without IL-7 (36 hours), was
measured using FITC-conjugated Annexin-V antibody and PI as previously described. (C) Viability of D1 and
SMoR cell lines, without IL-7 for the hours indicated, was determined by assessing morphological changes using
FSC and SSC gating as previously described. (D) CFSE-labeled cells were cultured with IL-7 for 72 hours.
Generation time, as indicated by loss of CFSE label, was assessed by flow cytometry as described in Methods.
Histograms display the fluorescence profile of CFSE-labeled cells analyzed using proliferation software (DeNovo).
The percent of cells in the peak generation for each cell line is shown. Lines indicate undivided cells and peaks
indicate divided cells. Tables at the far right display the number of generations within the experimental period for
each cell line. (E) Histograms show IL-7R surface expression in D1 and SMoR cells in the presence or absence of
IL-7 for 18 hours, using a specific PE-conjugated anti-IL-7 antibody, analyzed by flow cytometry. Table shows the
mean for each peak and the percent of IL-7R expression compared to the maximum level achieved in the absence of
IL-7. (F) D1 and SMoR cells were cultured in the presence of IL-7 and limiting glucose concentrations for 114
hours. Viability was determined by cell morphology, assessing size (forward scatter (FSC)) and granularity (side
scatter (SSC)) by flow cytometry. Results shown are representative of three experiments. * P < 0.05, ***P < 0.0001.
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Figure 13. The distribution of acidic vesicles is altered in the absence of Bim.
(A) Intracellular pH of D1 and SMoR cell lines was measured in the absence of IL-7 at times indicated in the figure
using flow cytometric analysis of BCECF-AM fluorescence, assessing the ratio at 525 nm and 610 nm. Results were
determined from calibrated pH standards as described in Materials and Methods. (B) Lymph node T-cells isolated
from WT C57BL/6 or BimKO mice, either freshly isolated (fresh) or cultured with 150 ng/ml of IL-7 (cultured) for
4 days, were assessed for pH, as determined by flow cytometric analysis of BCECF-AM fluorescence described
above. (C-E) Live cell confocal microscopy images of D1 cells (C) in the presence or absence of IL-7 for 20 hours
are shown. Cells were loaded with LysoSensor as described in Materials and Methods. IL-7-deprived D1 cells,
containing either non-targeting control (NT) or Bim siRNA (D), were loaded with LysoSensor and imaged as
described above. SMoR cells (E) grown with or without IL-7 were loaded with Lysosensor and imaged as described
above. Yellow color indicates fluorescence of intracellular vesicles at a more neutral pH acquired at emissions
445/615, and blue color indicates fluorescence of vesicles at acidic pH acquired at 525/640 nm. Colors were
arbitrarily chosen. Fluorescent images were obtained using the UltraView spinning disc confocal system
(PerkinElmer) with AxioObserver.Z1 (Carl Zeiss) stand, and a Plan-Apochromat 40x/1.4 Oil DIC objective. For (CE), images were obtained from Z-series collections and 3D projections developed using Velocity software. Arrows
indicate regions of interest or intensity/merged vesicle staining. Images are representative “snapshots” of three or
more independent experiments. ***P < 0.001
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Figure 14. Treatment with 3-MA accelerated cell death induced by IL-7 withdrawal but not in Bim deficient
cells.
D1 and SMoR cells, cultured with or without IL-7 for 18 hours, were treated with 3-MA (5 mM) as described in
Materials and Methods. Cell death was assessed by measuring phosphatidyl serine surface exposure and membrane
permeability with a FITC-conjugated Annexin-V antibody and PI staining using flow cytometry. Dot plots show
percentages representing the population of cells that are non-apoptotic (lower right quadrant), early apoptotic (upper
right quadrant) or late apoptotic/necrotic (upper left quadrant). Quadrants were established using controls. Results
shown are representative of four independent assays.
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Figure 15. The degradative phase of autophagy is impaired by Bim loss.
(A) D1 and SMoR cells were grown with or without IL-7 for 6 or 18 hours, and whole cell lysates were prepared as
described in Methods. Lysates were immunoblotted with specific antibodies for LC3 to examine levels of LC3-I and
LC3-II as well as p62. Quantitation of bands was performed using ImageJ software and is the average of 3
measurements taken per band. p38 MAPK is included as a loading control. Protein levels of LC3 and p62 were
normalized to p38 MAPK and percentages of protein detected shown are relative to samples from D1 cells cultured
18 hours with IL-7. (B) Whole cell lysates were prepared from primary LN cells freshly isolated from WT and
BimKO mice and immunoblotted for LC3 and p62 as described above. Cells were treated with 3-MA (5 mM) or
chloroquine (CQ) (25 µM) for six hours prior to lysis. p38 MAPK is shown as a loading control and quantitation of
bands was performed as described in (A) with percentages of protein shown relative to untreated WT cells. (C-D)
D1 and SMoR cells were cultured with or without IL-7 for 6 hours and treated with 3-MA or CQ as described
above. Lysates were immunoblotted for LC3 (C) and p62 (D) following protocols described above. p38 MAPK is
shown as a loading control for each blot and quantitation of bands was determined as described in (A) with
percentages of proteins shown relative to D1 cells untreated and cultured with IL-7. Results are representative of
three independent experiments. Images from full-length blots were cropped for concise presentation.
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Figure 16. Bim deficient cells are resistant to inhibition of lysosomal activity.
(A) Cytokine-withdrawal induced death of D1 and SMoR cells cultured without IL-7 and either DMSO (vehicle
control) or 50 µM pan-cathepsin inhibitor (Cathepsin inhibitor III (CI)) was measured by surface expression of
phosphatidyl serine using a FITC-conjugated Annexin-V antibody. Membrane permeability was assessed by
propidium iodide exclusion (PI) and analyzed by flow cytometry. Dot plots show percentages representing the
population of cells that are non-apoptotic (lower left quadrant), early apoptotic (upper left) or late apoptotic/necrotic
(upper right). Quadrants were established using controls. (B) D1 and SMoR cells cultured without IL-7 and either
DMSO (vehicle control), 5 µM Pepstatin A (cathepsin D inhibitor), or 10 µM Ca074 (cathepsin B inhibitor) for
times indicated, were assessed for viability as determined by cell morphology, assessing size (forward scatter (FSC))
and granularity (side scatter (SSC)) by flow cytometry. (C) D1 and SMoR cells cultured with IL-7 or without IL-7
and 25µM chloroquine (25CQ) were assayed for Annexin-V/PI staining by flow cytometry as described
above. Percentages represent the population of cells indicated by the highlighted boxes of late apoptotic or necrotic
cells. Results shown are representative of four experiments. (D-E) CFSE-labeled T-cells were adoptively transferred
to either Rag knockout (Rag-/-) or IL-7/Rag double knockout (IL-7-/-/Rag-/-) that were irradiated as described in
Materials and Methods. Mice were untreated or treated with chloroquine (CQ) (i.p. 60 mg/kg/mouse) 24 and 48
hours after transfer of cells. Mice were sacrificed after 72 hours and organs analyzed for T-cell recovery. Number of
generations recovered from transferred WT cells (D) and BimKO cells (E) were determined by loss of CFSE label
using cell proliferation software (DeNovo). Representative results from duplicate experiments are shown.
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Figure 17. BimL associates with lysosomes through interactions with dynein.
(A) A representative immunoblot is shown of lysates enriched for lysosomal content from D1 cells. D1 cells were
cultured in the presence or absence of IL-7 for 20 hours and subjected to differential ultracentrifugation. Gradient
fractions (17-30% Optiprep, Fractions 1-10), whole cell lysate (W), pellets (P) and supernatant (S) after initial
centrifugation step, were immunoblotted for Lamp1 (late endosome and lysosomal membrane), prohibitin
(mitochondria), Rab5 (early endosome), Bcl-2, and Bim. (B) Immunoblot analysis of enriched lysosomal protein
lysates were prepared from SMoR cells cultured in the presence or absence of IL-7 for 20 hours as described for D1
cells above. (A) Blots are representative of nine independent experiments. (C) Immunoblots show coimmunoprecipitation of dynein with Lamp1 upon presence of BimL. As input controls, the whole cell lysates before
immunoprecipitation are included. Whole cell lysates of D1 and SMoR cells cultured were with or without IL-7 for
20 hours incubated with either dynein or control antibody to co-immunoprecipitate binding proteins, subjected to
SDS-PAGE and immunoblotted for lysosomal/late endosomal protein (Lamp1), and early endosomal content
(Rab5). (D) Whole cell lysates of SMoR cells transfected with retrovirus to express individual Bim isoforms as
described in Methods, co-immunoprecipitated with either dynein or control antibody, were immunoblotted for
lysosomal/late endosomal protein (Lamp1), early endosomal protein (Rab5), and Bim. A representative experiment
of three performed is shown. Images from full-length blots were cropped for concise presentation.
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Figure 18. Expression of BimL restores lysosomal distribution in SMoR cells.
Live cell confocal microscopy images of SMoR cells are shown. Images are representative “snapshots” taken at the
end of a 24 hour live-imaging experiment. SMoR cells were retrovirally transfected to express the control plasmid,
pMIG (A), or the individual Bim isoforms, BimEL (B), BimL (C) and BimS (D), in the presence of IL-7, and loaded
with 1µM LysoTracker. Images were acquired using the UltraView spinning disc confocal system (PerkinElmer)
with AxioObserver.Z1 (Carl Zeiss) stand, and a Plan-Apochromat 40x/1.4 Oil DIC objective. Each field contains the
same cells but with different fluorescent channels: GFP fluorescence (upper left), RFP (LysoTracker) fluorescence
(upper right), DIC (lower left), and overlay of GFP and RFP fluorescence (lower right). Each panel also contains a
larger, digitally magnified inset of the overlay, as indicated by a white cutout within the overlay panel. The
magnification inset contains transfected cells indicated by (*). The bottom left panel of each figure section is a
density plot displaying the viability of SMoR cells expressing control or Bim isoforms. Cell death was assessed by
Sytox uptake (membrane permeability) and membrane asymmetry. Dot plots percentages represent the population of
cells that are non-apoptotic (lower right quadrant), early apoptotic (lower left) or late apoptotic/necrotic (upper left).
Quadrants were established using controls. Results shown are representative of three experiments.
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Discussion
In this study, using Bim-containing and Bim-deficient T-cells, we examined the function
of Bim during apoptosis and the degradative phase of autophagy controlled by IL-7 stimulation
and determined that the major isoforms of Bim contribute independently to these processes. We
found that BimL may facilitate lysosomal positioning in cells responding to IL-7 through
interactions with dynein.

We also observed that loss of IL-7 up-regulated total Bim

transcription, and that Bim deficiency partially protected these cells from death induced by IL-7
withdrawal, suggesting that the other isoforms participated in the intrinsic pathway of apoptosis.
In support, we found that T-cells lacking functional Bim had decreased growth rate, increased
endosomal and reduced lysosomal content, and were resistant to the effects of cathepsin
inhibition or impairment of lysosomal acidification. Over-expression of BimL in Bim deficient
cells increased vesicular aggregation, while BimEL, and more so BimS, overexpression
increased apoptotic morphology. Taken together, these results demonstrated that the major
isoforms of Bim could have distinct activities in T-cells that were indicated by localization to
different organelles.
Based on our studies, and others, it can be surmised that T-cells lacking Bim would be
deficient in the ability of lysosomes to degrade intracellular contents. Hence Bim-deficient Tcells would not effectively degrade autophagic vesicles or initiate lysosome-mediated apoptotic
events [189]. As a result, Bim deficient T-cells would be delayed undergoing cell death, but,
lacking the lysosomal degradative machinery, would eventually succumb perhaps to nutrient
deprivation or metabolic suicide. It is also possible that a limited form of autophagy could occur
in the absence of Bim. Under some conditions, the contents of autophagic vesicles can be
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degraded by amphisomes, autophagic vacuoles formed through the fusion of endosomes to
autophagosomes [190]. In Bim-deficient cells, we detected increased amounts of Rab5, an early
endosome marker, suggesting the fusion of early endosomes was possible and could, during
autophagy, perhaps form amphisomes in the absence of forming autolysosomes. There is also
the possibility that with reduced lysosomal activities, degradation via the proteosome could be
impaired [191].

p62 is primarily degraded by lysosomes and proteasomes [192], hence, this

could explain why incomplete degradation and accumulation of p62 occurs, and why CQ and 3MA treatments have little effect on Bim deficient SMoR cells.
Previous studies demonstrated that Bim is sequestered by dynein in healthy cells, and
dissociates upon an apoptotic stimulus; providing a possible regulatory mechanism [77, 193].
However, the viability of T-cells transfected with a BH3 domain mutant of BimL was increased
[47]. This suggested a possibility that beyond sequestering Bim, the interaction of BimL with
dynein facilitates the loading and perhaps fusion and positioning of lysosomes. In our study, IL7 withdrawal induced vesicular aggregation in T-cells containing Bim, while this was not
observed in Bim deficient T-cells. This result is supported by studies with dynein-deficient cells
in which endosomal and lysosomal content became dispersed and lysosomes ceased to colocalize with microtubules [194, 195]. Moreover, knockdown of Huntingtin (Htt), a scaffolding
protein that interacts with dynein, resulted in lysosomal accumulation and aggregation,
indicating that Htt was involved in the movement of cargo. In contrast, we found that Bim
deficiency resulted in dispersed vesicles and reduced aggregation, suggesting that Bim’s role
may not be in cargo movement but rather facilitating the fusion of late endosomes/lysosomes.
An example similar to Bim deficiency was seen in a study using mice deficient in Snapin, a
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SNARE-binding protein. Deletion of Snapin caused accumulation of endocytic organelles and
impaired lysosomal function and maturity [196]. These results support the possibility that the
dynein-binding motif on Bim, KXTQT [161], renders the protein accessible as an adaptor for
dynein during normal T-cell function to facilitate the positioning and fusion of lysosomal cargo.
The regulation of Bim transcription is mediated by the forkhead transcription factor,
FKHR-L1, in growth factor-deprived hematopoietic cells [49, 162]. This transcription factor,
also known as Foxo3a, translocates to the nucleus when the PI3-kinase/Akt pathway is downregulated in the absence of survival signals [58]. In neurons, under growth factor deprivation,
Bim was up-regulated but required Jun N-terminal protein kinases (JNK) activation [57, 188].
We show that IL-7 induced basal levels of bim gene transcription, even in non-apoptotic cells,
and that the withdrawal of IL-7 further amplified Bim synthesis. It may be that the JNK pathway
and the PI3K pathway, both shown to be active in response to IL-7 signaling [30, 45, 90], may
contribute to Bim expression in T-cells.

Interestingly, engagement of IL-7 induces the

internalization and further recycling of the IL-7R by proteasomes and lysosomes [197]. It is
possible that Bim, by enabling lysosomal degradative activities, could play a role in regulating
the amount of IL-7R available for membrane expression. In support, we found that in SMoR
cells IL-7R levels were slightly higher. Further evidence comes from a study in which cells were
cultured with IL-7 and treated with a clathrin formation inhibitor [197]. As a result, pAKT was
reduced, which in turn, stimulated FKHR-1 translocation and increased Bim synthesis, perhaps
to participate in the maintenance of IL-7R recycling [197].
Another way of controlling Bim levels includes regulation of alternative mRNA splicing.
For example, in B cells, engagement of the B cell receptor (BCR) led to BimL expression not
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through increased generation of BimL mRNA but rather through splicing of the BimEL mRNA.
Hence BimEL was a pre-mRNA form of BimL [64].

Additionally, phosphorylation sites

encoded by alternative splicing of exons within BimEL can contribute to BimL expression. As
example, in BimEL mutant mice lacking exon 3, which encodes sites of MAPK phosphorylation,
BimL expression resulted [68]. In our study, we observed more BimL protein compared to
BimEL in the presence of IL-7, suggesting that BimL was being produced in preference to
BimEL, perhaps through the splicing mechanism described above. In the absence of IL-7, we
noted increased total Bim mRNA and more BimEL protein, indicating that the possible splicing
of BimEL to make BimL was only occurring upon an IL-7 stimulus.
Our results indicate that the BimL isoform may have non-apoptotic activities that support
lysosome maintenance. Bim and IL-7R double-deficient mice showed partial restoration of
thymocyte development [44], while, in a bone marrow chimera, Bim deficiency failed to fully
reconstitute thymocyte development [52].

Bim deficiency, in our studies, failed to rescue

adoptively transferred T-cells in IL-7-/- hosts. The inability of Bim deficiency to completely
restore an immunodeficient phenotype could in part be explained by the redundancy of other proapoptotic proteins like Bad or Bid. However, another perspective could be that Bim isoforms
have both apoptosis (BimEL, and BimS) and cell maintenance or autophagic (BimL) activities.
Other apoptosis-regulating proteins have been shown to contribute to autophagy. For example,
anti-apoptotic Bcl-2 bound Beclin-1 and inhibited autophagic induction, but overexpression of
pro-apoptotic protein, Bad, induced autophagy in human cells [198]. Additionally, the lone C.
Elegans BH3-only protein, EGL-1, can trigger autophagy [199].

In studies examining the

individual isoforms of Bim, in which both BimL and Bcl-2 were expressed, BimL could not non-
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apoptotic function such as we have described. Moreover, expression of BimL did not cause
release of cytochrome c [76].
The implications of Bim isoforms having different cellular activities for disease
treatments are significant. In cancers with specific genetic mutations, Bim levels were found to
be predictive of the effect of inhibitors targeting PI3K, HER2 or EGFR, but did not correlate
with effectiveness to standard chemotherapeutics [200]. Efforts at developing inhibitory Bim
BH3-like mimetics for therapy only consider the pro-apoptotic action of Bim mediated, for
example, through the BH3 domain [201]. Our work suggests that Bim is more complex, having
multiple isoforms and functions. An alternative approach could be the design of compounds that
target the Bim isoform-splicing mechanisms. As a result, one could potentially control the
generation of a specific isoform to elicit the desired apoptotic (BimEL/S>BimL) or autophagic
(BimL>BimEL/S) outcome in a manner that is more effective than the targeting of total Bim.
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CHAPTER 4: CONCLUSIONS
IL-7 is a pleotropic cytokine, and promising as a therapeutic agent to support the immune
system. As of recently, IL-7 is being evaluated in 15 clinical trials as treatment for reconstitution
in lymphopenic patients, or after chemotherapy, in addition to patients with depleted immune
systems due to long term HIV infection. Unfortunately, assessment of the effects of IL-7 has
been limited to cell survivability and expansion of certain T cell subsets. However, as we’ve
shown here, IL-7 signaling mechanisms are more complex in T cells. Using our IL-7 dependent
T cell line, D1, and in vitro and in vivo models, we have been able to study how IL-7 signaling
contributes to the maintenance of T cells, specifically, in terms of metabolism and cell survival.
Specifically, we’ve found that IL-7 promoted HXKII gene expression in a Stat5-independent
manner, through the activity of JNK. JNK, in turn, drove the expression of JunD, a component
of the AP-1 transcription factors, and JunD homodimerization. These findings were significant
as both JNK and JunD are typically ascribed inhibitory characteristics, so how JNK and JunD
could have both inhibitory and stimulatory functions necessitates further study. In addition to
stimulating metabolism, we found that IL-7 promoted growth and proliferation through the
activity of JunD, namely, in the expression of Pim-1. Finding that two factors involved in
growth and proliferation of T cells, HXKII and Pim-1, are regulated in a Stat5-independent
manner, establishes that IL-7 signaling pathways are more diverse than previously thought.
The studies that we have performed illustrate the wide-ranging possible effects of IL-7
signaling. Specifically, the bioinformatics completed demonstrates the large number of earlyresponse genes activated within a two-hour pulse with IL-7, with a potential JunD binding site
located within their promoter region. Some of these genes play critical roles in cell cycling,
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suppressing inflammation, and cell adhesion, perhaps contributing to T-cell migration to areas of
increased IL-7. We’ve also shown that increased glucose uptake occurs through JunD activation,
perhaps leading to increased rates of glycolysis. Bioinformatics has provided a plethora of
potentially IL-7-mediated, JunD-regulated genes to investigate, and future studies could reveal
additional mechanisms involved in glucose consumption that were previously unknown.
Cancer cells preferentially metabolize glucose through aerobic glycolysis, termed the
Warburg effect [202]. Recent studies have attempted to find methods in which to regulate cancer
cell metabolism, and in turn, inhibit metastasis of invasive tumors.

Cancer cells contain

mutations to retain immortality, including abnormalities in tumor-suppressor p53 [203], among
others. We and others have shown that JunD protects cells from both p53-dependent [145] and
p53- independent apoptosis [140]. Therapies developed to target JunD, or its downstream
effectors, could potentially eliminate the cancer cells that switch to glycolysis.
One future study should attempt to determine the involvement of JNK in IL-7 directed
JAK/Stat pathway. In our first study, we presented a mechanism for HXKII gene expression,
induced by IL-7 signaling, mediated through JNK activity, independent of Stat5. However,
under IL-7 deprivation conditions, JNK has been found to phosphorylate BimEL to induce
apoptosis [90]. One question to ask is why JNK can function in either the presence, or absence
of IL-7, with both pro- and anti-apoptotic activities. Therefore it is necessary to determine what
regulates JNK activity.
Previous studies have shown that in mice expressing constitutively active Stat5, IL-7 can
induce Pim-1 transcription in pro-B cells [94]. In studies included here, we’ve shown that basal
Pim-1 protein synthesis is IL-7 dependent, but independent of JNK. We also showed that IL-7
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re-addition induced Pim-1 expression, and that JNK inhibition could ablate it. It is possible that
Stat5 could regulate basal Pim-1 expression, and that JNK could initiate the synthesis of Pim-1.
Pim-1, a kinase dysregulated in several cancers, can be transcribed through Stat5 [94], but Pim-1
can modulate Stat5 transcription by binding its inhibitor, SOCS1 [97, 204]. Taken together,
these studies indicate that Pim-1 could potentially regulate its own expression.

Since

overexpression of Pim kinases result in lymphogenesis in mice [205], and Stat5 is a potential
chemotherapeutic target [206, 207], further study is necessary to evaluate what stimulus
maintains Pim-1 expression in these cancers, and if targeting a pathway other than Jak/Stat
would be more beneficial.
In addition to mediating cell growth, we’ve shown that IL-7 can regulate the maintenance
of T cell populations. Previous work has shown that Bim, a pro-apoptotic member of the Bcl-2
family, participates in activated T cell death [39]. However, those studying Bim have all but
ceased further examination investigating the possibility of separate functions per individual
isoform. In our own studies, we have confirmed the involvement of Bim in apoptosis, and
furthermore, the binding Bim to the dynein light chain [77]. Conversely, we have established
that individual isoforms of Bim have different functions, namely, BimL participates in the
stabilization of lysosomes, and in progressing the process of autophagy, while BimEL and BimS
participate in apoptotic activities. Instead of observing the sequestering of Bim as to prevent
apoptosis, we found an unexpected protective function of BimL, helpful in stress conditions.
Autophagy allows cell scavenging when the environment is deficient in essential nutrients,
which is most often when a peripheral T cell is circulating until encountering IL-7 or other
factors. These findings are significant in that they establish pro- and anti- survival properties of
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Bim, and illustrate deleterious effects if Bim is targeted therapeutically. Hence, taken together,
our studies clearly demonstrate the importance for an understanding on how IL-7 signal
transduction consequently affects gene expression in T cells, to further therapeutic development
of this cytokine.
We’ve shown that the lack of IL-7 up-regulates total Bim gene expression, and that the
presence of IL-7 maintains basal Bim levels. Recently, Clybouw and colleagues found that BCR
stimulation up-regulated the production of BimL, not transcriptionally, but rather, BimL mRNA
resulted from intron retention within BimEL mRNA [64]. An interesting study to undertake
would determine if IL-7 maintains basal Bim expression, specifically to increase BimL
transcription and further, protein expression, and whether IL-7 directs BimL expression through
the conversion of BimEL mRNA to BimL. As alternative splicing contributes to the expression
of BimL, splicing can also be influenced by microRNA (miRNA) activity. MiRNA inhibits gene
expression by associating with target mRNA, contributing to the degradation and silencing of its
target [65]. In fact, epiblasts deficient in Dicer, an enzyme necessary for the creation of miRNA,
have increased expression of Bim [208]. How miRNA regulation of Bim expression contributes
to BimL protein stability, and its involvement in autophagy induction needs further study.
A recent study has concluded that BimEL and BimL are interchangeable for apoptotic
function in homeostatic hematopoiesis [66], but have not evaluated the individual isoforms in
other context other than degree of apoptosis upon treatment with immunosuppressors. In T cells
where phosphorylation of Bim is impaired, these cells activate upon mitogen stimulation, and
proliferate, to the same extent as wild type cells [66]. These results indicate that the integrity of
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Bim could be essential for T cell activation and subsequently, mounting an immune response,
and that BimEL degradation is not critical to the regulation of apoptosis.
Since the three major isoforms have different phosphorylation sites, regulatory targeting
sequences, and lysosome recognition motifs, the question remains as to why BimL has prosurvival functions, while the other isoforms are pro-apoptotic.

Furthermore, there is

inconsistency as to whether phosphorylation stimulates Bim activity or targets these isoforms for
ubiquitination, or other forms of degradation. Especially since a major phosphorylation site
within BimL, Thr56, lies within a lysosomal targeting sequence, it is essential to determine
whether the phosphorylation status of this region contributes to lysosomal stability or trafficking
and the degradative phase of autophagy. It’s interesting to note that this site can also be found in
BimEL, but as of this writing, studies evaluating whether this site is physiologically significant
to the function of BimEL have not been published. Additionally, it would be beneficial to
determine whether the BH3 domain of BimL is modified in some manner, and whether this
contributes to the possible pro-survival function of BimL.
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Figure 19. Novel IL-7-mediated signaling pathways.
IL-7 contributes to the survival of cells by mediating Jak/Stat5 activities and inducing synthesis of antiapoptotic genes, such as Bcl-Xl, and SOCS1. IL-7 stimulates proliferation by activating CDC25A
phosphatase, and initiates lymphocyte movement by down-regulating the extracellular adhesion molecule,
CD62L. The studies included in this dissertation illustrate novel IL-7 signaling pathways that contribute
to cell proliferation and survival that were previously unknown, including regulation of HXKII gene
expression transduced JunD and JNK activity, and also, regulation of BimL and its potential contribution
to lysosome trafficking or stability.
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